Trial Outcomes & Findings for A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112 (NCT NCT03116113)
NCT ID: NCT03116113
Last Updated: 2024-01-18
Results Overview
DLTs are defined as any of the following events considered to be related to study drug: Sustained decrease in best-corrected visual acuity (BCVA) of ≥30 letters on the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart compared to baseline (sustained is defined as lasting 48 hours or more until recovery, with recovery defined as visual acuity (VA) returning to within 10 letters of baseline VA. An exception is made for surgery-related events occurring in close temporal association {within \<24 hours} of the surgery); Vitreous inflammation, vitritis (\>Grade 3 using standardized Nussenblatt vitreous inflammation scale grading); Any clinically significant retinal damage observed that is not directly attributed to complications of surgery; Any clinically relevant suspected unexpected serious adverse reaction, with the exception of vision loss or vision threatening.
COMPLETED
PHASE1/PHASE2
50 participants
Up to Month 24
2024-01-18
Participant Flow
Participants were enrolled at investigational sites in the United Kingdom (UK) and the United States (US) from 08 March 2017 to 18 November 2020.
A total of 50 participants with X-Linked Retinitis Pigmentosa (XLRP) were enrolled in the study (18 participants in Part 1 and 32 participants in Part 2). Of these, 47 participants completed the study (18 participants in Part 1 and 29 in Part 2).
Participant milestones
| Measure |
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vector genomes {vg} ) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
|
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|---|---|---|
|
Part 1 (Day 0 up to Month 24)
STARTED
|
3
|
3
|
3
|
3
|
3
|
3
|
0
|
0
|
0
|
|
Part 1 (Day 0 up to Month 24)
COMPLETED
|
3
|
3
|
3
|
3
|
3
|
3
|
0
|
0
|
0
|
|
Part 1 (Day 0 up to Month 24)
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Part 2 (Month 25 up to Month 36)
STARTED
|
0
|
0
|
0
|
0
|
0
|
0
|
9
|
11
|
12
|
|
Part 2 (Month 25 up to Month 36)
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
9
|
10
|
10
|
|
Part 2 (Month 25 up to Month 36)
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
Reasons for withdrawal
| Measure |
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vector genomes {vg} ) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 2: Untreated Group
Participants received no intervention to allow for a controlled comparison.
|
Part 2: BIIB112 Low Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 2: BIIB112 High Dose
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|---|---|---|
|
Part 2 (Month 25 up to Month 36)
Withdrew due to Coronavirus 2019COVID-19
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
Baseline Characteristics
A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112
Baseline characteristics by cohort
| Measure |
Part 1: BIIB112 Dose 1
n=3 Participants
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=3 Participants
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=3 Participants
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 4
n=3 Participants
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=3 Participants
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=3 Participants
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 2: Untreated Group
n=9 Participants
Participants received no intervention to allow for a controlled comparison.
|
Part 2: BIIB112 Low Dose
n=11 Participants
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 2: BIIB112 High Dose
n=12 Participants
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Total
n=50 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
36.3 years
STANDARD_DEVIATION 6.35 • n=99 Participants
|
34.3 years
STANDARD_DEVIATION 10.69 • n=107 Participants
|
30.0 years
STANDARD_DEVIATION 2.65 • n=206 Participants
|
33.3 years
STANDARD_DEVIATION 14.57 • n=7 Participants
|
25.0 years
STANDARD_DEVIATION 5.00 • n=31 Participants
|
32.3 years
STANDARD_DEVIATION 15.31 • n=30 Participants
|
33.7 years
STANDARD_DEVIATION 13.83 • n=3 Participants
|
30.6 years
STANDARD_DEVIATION 8.83 • n=6 Participants
|
26.8 years
STANDARD_DEVIATION 7.11 • n=114 Participants
|
30.7 years
STANDARD_DEVIATION 9.75
|
|
Sex: Female, Male
Female
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=114 Participants
|
0 Participants
|
|
Sex: Female, Male
Male
|
3 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
3 Participants
n=7 Participants
|
3 Participants
n=31 Participants
|
3 Participants
n=30 Participants
|
9 Participants
n=3 Participants
|
11 Participants
n=6 Participants
|
12 Participants
n=114 Participants
|
50 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
1 Participants
n=30 Participants
|
2 Participants
n=3 Participants
|
3 Participants
n=6 Participants
|
5 Participants
n=114 Participants
|
11 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
3 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
3 Participants
n=7 Participants
|
3 Participants
n=31 Participants
|
2 Participants
n=30 Participants
|
7 Participants
n=3 Participants
|
8 Participants
n=6 Participants
|
7 Participants
n=114 Participants
|
39 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=114 Participants
|
0 Participants
|
|
Race/Ethnicity, Customized
Race · Asian
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=6 Participants
|
0 Participants
n=114 Participants
|
1 Participants
|
|
Race/Ethnicity, Customized
Race · Black or African American
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=6 Participants
|
0 Participants
n=114 Participants
|
1 Participants
|
|
Race/Ethnicity, Customized
Race · White
|
3 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
3 Participants
n=7 Participants
|
3 Participants
n=31 Participants
|
3 Participants
n=30 Participants
|
6 Participants
n=3 Participants
|
9 Participants
n=6 Participants
|
12 Participants
n=114 Participants
|
45 Participants
|
|
Race/Ethnicity, Customized
Race · More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
1 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=114 Participants
|
1 Participants
|
|
Race/Ethnicity, Customized
Race · Other
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=30 Participants
|
2 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=114 Participants
|
2 Participants
|
PRIMARY outcome
Timeframe: Up to Month 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112).
DLTs are defined as any of the following events considered to be related to study drug: Sustained decrease in best-corrected visual acuity (BCVA) of ≥30 letters on the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart compared to baseline (sustained is defined as lasting 48 hours or more until recovery, with recovery defined as visual acuity (VA) returning to within 10 letters of baseline VA. An exception is made for surgery-related events occurring in close temporal association {within \<24 hours} of the surgery); Vitreous inflammation, vitritis (\>Grade 3 using standardized Nussenblatt vitreous inflammation scale grading); Any clinically significant retinal damage observed that is not directly attributed to complications of surgery; Any clinically relevant suspected unexpected serious adverse reaction, with the exception of vision loss or vision threatening.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=3 Participants
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=3 Participants
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=3 Participants
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=3 Participants
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=3 Participants
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=3 Participants
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Number of Participants With Dose-Limiting Toxicities (DLTs)
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Day 0 (surgery) in Part 1 of the study up to 24 monthsPopulation: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112).
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAEs are defined as the AEs starting or worsening on or after the day of the first surgery.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=3 Participants
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=3 Participants
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=3 Participants
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=3 Participants
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=3 Participants
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=3 Participants
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
|
3 Participants
|
3 Participants
|
3 Participants
|
3 Participants
|
3 Participants
|
3 Participants
|
PRIMARY outcome
Timeframe: Month 12Population: Intent-to-treat (ITT) analysis set included all participants that were randomized under the 3-arm randomization schedules. "Overall number of participants analyzed" signifies the number of participants with data available for analysis of this outcome measure.
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '\< 0', '0', or a positive integer. The point labelled as '\< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in center grid was defined as an increase from baseline of 7 or more dBs in any 5 or more points out of the 16 central points.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=9 Study eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=8 Study eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=8 Study eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 2: Percentage of Study Eyes With ≥7 Decibels (dB) Improvement From Baseline at ≥5 Points Out of the 16 Central Loci Points of the 10-2 Grid Assessed by Macular Integrity Assessment (MAIA) Microperimetry
|
—
|
—
|
—
|
22.2 percentage of study eyes
Interval 6.1 to 49.0
|
37.5 percentage of study eyes
Interval 14.7 to 65.5
|
25.0 percentage of study eyes
Interval 6.9 to 53.8
|
PRIMARY outcome
Timeframe: Day 0 (surgery) in Part 2 of the study up to 12 monthsPopulation: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112).
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAEs are defined as AEs starting on or after the day of the first surgery.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=9 Participants
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=11 Participants
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=12 Participants
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 2: Number of Participants With TEAEs
|
—
|
—
|
—
|
5 Participants
|
11 Participants
|
12 Participants
|
SECONDARY outcome
Timeframe: Months 1, 3, 6, 9, 12, 18, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure. 'Number of participants analyzed' signifies the number of participants with data available for analysis at specified timepoint.
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '\< 0', '0' or a positive integer. The point labelled as '\< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in center grid was defined as an increase from baseline of 7 or more dBs in any 5 or more points out of the 16 central points.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=3 study eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=3 study eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=3 study eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=3 study eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=2 study eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=3 study eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Month 1
|
33.3 percentage of study eyes
Interval 0.8 to 90.6
|
33.3 percentage of study eyes
Interval 0.8 to 90.6
|
33.3 percentage of study eyes
Interval 0.8 to 90.6
|
0.0 percentage of study eyes
Interval 0.0 to 70.8
|
0.0 percentage of study eyes
Interval 0.0 to 84.2
|
100.0 percentage of study eyes
Interval 29.2 to 100.0
|
|
Part 1: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Month 3
|
33.3 percentage of study eyes
Interval 0.8 to 90.6
|
33.3 percentage of study eyes
Interval 0.8 to 90.6
|
0.0 percentage of study eyes
Interval 0.0 to 70.8
|
0.0 percentage of study eyes
Interval 0.0 to 70.8
|
0.0 percentage of study eyes
Interval 0.0 to 84.2
|
66.7 percentage of study eyes
Interval 9.4 to 99.2
|
|
Part 1: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Month 6
|
33.3 percentage of study eyes
Interval 0.8 to 90.6
|
0.0 percentage of study eyes
Interval 0.0 to 70.8
|
33.3 percentage of study eyes
Interval 0.8 to 90.6
|
0.0 percentage of study eyes
Interval 0.0 to 70.8
|
0.0 percentage of study eyes
Interval 0.0 to 84.2
|
66.7 percentage of study eyes
Interval 9.4 to 99.2
|
|
Part 1: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Month 9
|
33.3 percentage of study eyes
Interval 0.8 to 90.6
|
0.0 percentage of study eyes
Interval 0.0 to 70.8
|
33.3 percentage of study eyes
Interval 0.8 to 90.6
|
0.0 percentage of study eyes
Interval 0.0 to 70.8
|
0.0 percentage of study eyes
Interval 0.0 to 84.2
|
66.7 percentage of study eyes
Interval 9.4 to 99.2
|
|
Part 1: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Month 12
|
33.3 percentage of study eyes
Interval 0.8 to 90.6
|
50.0 percentage of study eyes
Interval 1.3 to 98.7
|
33.3 percentage of study eyes
Interval 0.8 to 90.6
|
0.0 percentage of study eyes
Interval 0.0 to 70.8
|
0.0 percentage of study eyes
Interval 0.0 to 84.2
|
33.3 percentage of study eyes
Interval 0.8 to 90.6
|
|
Part 1: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Month 18
|
33.3 percentage of study eyes
Interval 0.8 to 90.6
|
0.0 percentage of study eyes
Interval 0.0 to 70.8
|
0.0 percentage of study eyes
Interval 0.0 to 84.2
|
0.0 percentage of study eyes
Interval 0.0 to 70.8
|
0.0 percentage of study eyes
Interval 0.0 to 84.2
|
66.7 percentage of study eyes
Interval 9.4 to 99.2
|
|
Part 1: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Month 24
|
33.3 percentage of study eyes
Interval 0.8 to 90.6
|
0.0 percentage of study eyes
Interval 0.0 to 70.8
|
0.0 percentage of study eyes
Interval 0.0 to 70.8
|
0.0 percentage of study eyes
Interval 0.0 to 70.8
|
0.0 percentage of study eyes
Interval 0.0 to 97.5
|
33.3 percentage of study eyes
Interval 0.8 to 90.6
|
SECONDARY outcome
Timeframe: Months 1, 3, 6, 9, 12, 18, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure. 'Number of participants analyzed' signifies the number of participants with data available for analysis at specified timepoint.
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '\< 0', '0' or a positive integer. The point labelled as '\< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in whole grid was defined as an increase from baseline of 7 or more dBs in any 5 or more points of the grid as a whole (68 points).
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=3 study eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=3 study eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=3 study eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=3 study eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=2 study eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=3 study eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 68 Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Month 1
|
33.3 percentage of study eyes
Interval 0.8 to 90.6
|
33.3 percentage of study eyes
Interval 0.8 to 90.6
|
33.3 percentage of study eyes
Interval 0.8 to 90.6
|
0.0 percentage of study eyes
Interval 0.0 to 70.8
|
0.0 percentage of study eyes
Interval 0.0 to 84.2
|
100.0 percentage of study eyes
Interval 29.2 to 100.0
|
|
Part 1: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 68 Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Month 3
|
33.3 percentage of study eyes
Interval 0.8 to 90.6
|
33.3 percentage of study eyes
Interval 0.8 to 90.6
|
66.7 percentage of study eyes
Interval 9.4 to 99.2
|
0.0 percentage of study eyes
Interval 0.0 to 70.8
|
0.0 percentage of study eyes
Interval 0.0 to 84.2
|
66.7 percentage of study eyes
Interval 9.4 to 99.2
|
|
Part 1: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 68 Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Month 6
|
33.3 percentage of study eyes
Interval 0.8 to 90.6
|
66.7 percentage of study eyes
Interval 9.4 to 99.2
|
100.0 percentage of study eyes
Interval 29.2 to 100.0
|
0.0 percentage of study eyes
Interval 0.0 to 70.8
|
0.0 percentage of study eyes
Interval 0.0 to 84.2
|
100.0 percentage of study eyes
Interval 29.2 to 100.0
|
|
Part 1: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 68 Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Month 9
|
33.3 percentage of study eyes
Interval 0.8 to 90.6
|
66.7 percentage of study eyes
Interval 9.4 to 99.2
|
66.7 percentage of study eyes
Interval 9.4 to 99.2
|
0.0 percentage of study eyes
Interval 0.0 to 70.8
|
0.0 percentage of study eyes
Interval 0.0 to 84.2
|
66.7 percentage of study eyes
Interval 9.4 to 99.2
|
|
Part 1: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 68 Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Month 12
|
66.7 percentage of study eyes
Interval 9.4 to 99.2
|
50.0 percentage of study eyes
Interval 1.3 to 98.7
|
66.7 percentage of study eyes
Interval 9.4 to 99.2
|
0.0 percentage of study eyes
Interval 0.0 to 70.8
|
50.0 percentage of study eyes
Interval 1.3 to 98.7
|
66.7 percentage of study eyes
Interval 9.4 to 99.2
|
|
Part 1: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 68 Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Month 18
|
33.3 percentage of study eyes
Interval 0.8 to 90.6
|
66.7 percentage of study eyes
Interval 9.4 to 99.2
|
50.0 percentage of study eyes
Interval 1.3 to 98.7
|
0.0 percentage of study eyes
Interval 0.0 to 70.8
|
50.0 percentage of study eyes
Interval 1.3 to 98.7
|
66.7 percentage of study eyes
Interval 9.4 to 99.2
|
|
Part 1: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 68 Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Month 24
|
66.7 percentage of study eyes
Interval 9.4 to 99.2
|
33.3 percentage of study eyes
Interval 0.8 to 90.6
|
33.3 percentage of study eyes
Interval 0.8 to 99.2
|
0.0 percentage of study eyes
Interval 0.0 to 70.8
|
0.0 percentage of study eyes
Interval 0.0 to 97.5
|
33.3 percentage of study eyes
Interval 0.8 to 90.6
|
SECONDARY outcome
Timeframe: Baseline, Months 1, 3, 6, 9, 12, 18, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure. 'Number of participants analyzed' signifies the number of participants with data available for analysis at specified timepoint.
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '\< 0', '0' or a positive integer. The point labelled as '\< 0' is assigned a value of '-1' by MAIA in the calculation. Improvement in mean sensitivity in center grid was defined as an increase from baseline of 7 or more dBs in any 5 or more points out of the 16 central points. Here negative values indicate a decline in retinal sensitivity.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=4 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points Assessed by MAIA Microperimetry
Baseline: Study Eye
|
6.52 dBs
Standard Deviation 3.398
|
13.46 dBs
Standard Deviation 6.316
|
7.75 dBs
Standard Deviation 7.742
|
0.33 dBs
Standard Deviation 1.748
|
1.78 dBs
Standard Deviation 1.282
|
3.35 dBs
Standard Deviation 0.911
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points Assessed by MAIA Microperimetry
Baseline: Non-Study Eye
|
8.21 dBs
Standard Deviation 5.570
|
13.71 dBs
Standard Deviation 8.447
|
7.54 dBs
Standard Deviation 7.542
|
0.23 dBs
Standard Deviation 1.358
|
3.31 dBs
Standard Deviation 2.563
|
6.92 dBs
Standard Deviation 2.221
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 1: Study Eye
|
1.19 dBs
Standard Deviation 6.094
|
-0.63 dBs
Standard Deviation 4.154
|
-1.90 dBs
Standard Deviation 7.686
|
0.52 dBs
Standard Deviation 0.477
|
-0.09 dBs
Standard Deviation 0.928
|
6.10 dBs
Standard Deviation 0.844
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 1: Non-Study Eye
|
-0.19 dBs
Standard Deviation 0.272
|
1.40 dBs
Standard Deviation 2.690
|
0.19 dBs
Standard Deviation 2.063
|
0.42 dBs
Standard Deviation 1.122
|
-0.81 dBs
Standard Deviation 1.768
|
-0.98 dBs
Standard Deviation 1.531
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 3: Study Eye
|
1.73 dBs
Standard Deviation 8.714
|
-3.58 dBs
Standard Deviation 7.476
|
-3.35 dBs
Standard Deviation 2.894
|
0.40 dBs
Standard Deviation 0.407
|
0.47 dBs
Standard Deviation 1.282
|
5.63 dBs
Standard Deviation 2.394
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 3: Non-Study Eye
|
0.33 dBs
Standard Deviation 1.134
|
2.06 dBs
Standard Deviation 1.137
|
-0.42 dBs
Standard Deviation 0.289
|
-0.06 dBs
Standard Deviation 0.534
|
-0.91 dBs
Standard Deviation 0.575
|
-1.15 dBs
Standard Deviation 2.094
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 6: Study Eye
|
3.25 dBs
Standard Deviation 8.199
|
-2.38 dBs
Standard Deviation 5.177
|
0.85 dBs
Standard Deviation 5.105
|
0.54 dBs
Standard Deviation 0.485
|
-0.06 dBs
Standard Deviation 0.265
|
5.10 dBs
Standard Deviation 1.890
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 6: Non-Study Eye
|
2.10 dBs
Standard Deviation 3.437
|
2.19 dBs
Standard Deviation 0.933
|
-0.65 dBs
Standard Deviation 1.156
|
-0.17 dBs
Standard Deviation 0.344
|
-0.34 dBs
Standard Deviation 2.607
|
-1.19 dBs
Standard Deviation 1.535
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 9: Study Eye
|
3.69 dBs
Standard Deviation 6.308
|
-2.50 dBs
Standard Deviation 5.314
|
0.77 dBs
Standard Deviation 7.096
|
0.21 dBs
Standard Deviation 0.219
|
0.09 dBs
Standard Deviation 1.282
|
4.65 dBs
Standard Deviation 3.851
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 9: Non-Study Eye
|
-0.06 dBs
Standard Deviation 1.789
|
2.52 dBs
Standard Deviation 1.714
|
0.40 dBs
Standard Deviation 2.032
|
-0.35 dBs
Standard Deviation 0.509
|
0.19 dBs
Standard Deviation 2.210
|
0.20 dBs
Standard Deviation 2.751
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 12: Study Eye
|
3.98 dBs
Standard Deviation 5.090
|
2.25 dBs
Standard Deviation 2.121
|
0.56 dBs
Standard Deviation 5.590
|
0.19 dBs
Standard Deviation 0.272
|
0.13 dBs
Standard Deviation 1.945
|
4.10 dBs
Standard Deviation 2.908
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 12: Non-Study Eye
|
0.42 dBs
Standard Deviation 1.951
|
2.31 dBs
Standard Deviation 2.990
|
-0.29 dBs
Standard Deviation 1.835
|
-0.10 dBs
Standard Deviation 0.355
|
-1.09 dBs
Standard Deviation 1.370
|
-1.02 dBs
Standard Deviation 0.581
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 18: Study Eye
|
2.92 dBs
Standard Deviation 5.550
|
-2.79 dBs
Standard Deviation 6.733
|
-1.09 dBs
Standard Deviation 5.436
|
0.21 dBs
Standard Deviation 0.473
|
-1.13 dBs
Standard Deviation 0.177
|
2.69 dBs
Standard Deviation 2.507
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 18: Non-Study Eye
|
-0.67 dBs
Standard Deviation 0.806
|
1.92 dBs
Standard Deviation 3.085
|
-0.59 dBs
Standard Deviation 2.607
|
-0.33 dBs
Standard Deviation 0.577
|
-1.09 dBs
Standard Deviation 1.282
|
0.02 dBs
Standard Deviation 0.940
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 24: Study Eye
|
1.48 dBs
Standard Deviation 5.236
|
-4.90 dBs
Standard Deviation 5.250
|
-1.88 dBs
Standard Deviation 5.862
|
0.04 dBs
Standard Deviation 0.253
|
-1.88 dBs
Standard Deviation NA
Standard deviation (SD) cannot be estimated for 1 participant.
|
2.75 dBs
Standard Deviation 2.683
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 24: Non-Study Eye
|
-0.56 dBs
Standard Deviation 1.207
|
0.71 dBs
Standard Deviation 3.263
|
-2.19 dBs
Standard Deviation 2.189
|
-0.46 dBs
Standard Deviation 0.469
|
-1.63 dBs
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-0.33 dBs
Standard Deviation 1.347
|
SECONDARY outcome
Timeframe: Baseline, Months 1, 3, 6, 9, 12, 18, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure. 'Number of participants analyzed' signifies the number of participants with data available for analysis at specified timepoint.
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '\< 0', '0' or a positive integer. The point labelled as '\< 0' is assigned a value of '-1' by MAIA in the calculation. Improvement in mean sensitivity in whole grid was defined as an increase from baseline of 7 or more dBs in any 5 or more points of the grid as a whole (68 points). Here negative values indicate a decline in retinal sensitivity.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=4 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points Assessed by MAIA Microperimetry
Baseline: Study Eye
|
2.22 dBs
Standard Deviation 1.536
|
8.87 dBs
Standard Deviation 10.784
|
4.26 dBs
Standard Deviation 6.732
|
-0.19 dBs
Standard Deviation 0.690
|
0.20 dBs
Standard Deviation 0.281
|
0.21 dBs
Standard Deviation 0.435
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points Assessed by MAIA Microperimetry
Baseline: Non-Study Eye
|
2.30 dBs
Standard Deviation 1.559
|
9.11 dBs
Standard Deviation 12.466
|
5.35 dBs
Standard Deviation 8.579
|
-0.38 dBs
Standard Deviation 0.540
|
1.47 dBs
Standard Deviation 1.061
|
1.50 dBs
Standard Deviation 1.419
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 1: Study Eye
|
0.08 dBs
Standard Deviation 2.436
|
0.56 dBs
Standard Deviation 3.243
|
-1.69 dBs
Standard Deviation 4.341
|
0.12 dBs
Standard Deviation 0.309
|
0.24 dBs
Standard Deviation 1.185
|
2.42 dBs
Standard Deviation 0.283
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 1: Non-Study Eye
|
-0.11 dBs
Standard Deviation 0.111
|
1.24 dBs
Standard Deviation 1.639
|
-0.66 dBs
Standard Deviation 1.474
|
0.18 dBs
Standard Deviation 0.481
|
-0.76 dBs
Standard Deviation 1.165
|
-0.08 dBs
Standard Deviation 0.938
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 3: Study Eye
|
0.58 dBs
Standard Deviation 5.061
|
-1.87 dBs
Standard Deviation 4.073
|
-0.60 dBs
Standard Deviation 1.383
|
0.14 dBs
Standard Deviation 0.137
|
0.74 dBs
Standard Deviation 1.820
|
2.44 dBs
Standard Deviation 1.564
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 3: Non-Study Eye
|
0.68 dBs
Standard Deviation 1.223
|
1.38 dBs
Standard Deviation 1.005
|
-0.65 dBs
Standard Deviation 0.407
|
-0.06 dBs
Standard Deviation 0.292
|
-0.29 dBs
Standard Deviation 1.549
|
-0.29 dBs
Standard Deviation 1.351
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 6: Study Eye
|
0.90 dBs
Standard Deviation 5.011
|
-0.60 dBs
Standard Deviation 1.596
|
0.51 dBs
Standard Deviation 2.154
|
0.04 dBs
Standard Deviation 0.334
|
0.19 dBs
Standard Deviation 0.957
|
2.28 dBs
Standard Deviation 1.534
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 6: Non-Study Eye
|
3.86 dBs
Standard Deviation 5.648
|
1.76 dBs
Standard Deviation 0.470
|
-0.84 dBs
Standard Deviation 1.101
|
-0.24 dBs
Standard Deviation 0.331
|
-0.32 dBs
Standard Deviation 1.872
|
-0.51 dBs
Standard Deviation 0.773
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 9: Study Eye
|
0.90 dBs
Standard Deviation 4.233
|
-0.87 dBs
Standard Deviation 2.229
|
-0.13 dBs
Standard Deviation 4.044
|
-0.18 dBs
Standard Deviation 0.145
|
0.31 dBs
Standard Deviation 1.456
|
2.02 dBs
Standard Deviation 2.177
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 9: Non-Study Eye
|
0.77 dBs
Standard Deviation 1.405
|
2.05 dBs
Standard Deviation 0.816
|
-0.41 dBs
Standard Deviation 1.157
|
-0.37 dBs
Standard Deviation 0.467
|
-0.12 dBs
Standard Deviation 1.830
|
1.66 dBs
Standard Deviation 1.790
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 12: Study Eye
|
1.28 dBs
Standard Deviation 3.541
|
-0.22 dBs
Standard Deviation 2.600
|
-0.41 dBs
Standard Deviation 4.208
|
-0.16 dBs
Standard Deviation 0.165
|
0.30 dBs
Standard Deviation 1.612
|
1.72 dBs
Standard Deviation 1.892
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 12: Non-Study Eye
|
0.76 dBs
Standard Deviation 1.345
|
1.72 dBs
Standard Deviation 1.144
|
-0.82 dBs
Standard Deviation 1.248
|
-0.30 dBs
Standard Deviation 0.417
|
-0.46 dBs
Standard Deviation 1.633
|
-0.24 dBs
Standard Deviation 0.153
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 18: Study Eye
|
1.37 dBs
Standard Deviation 4.233
|
-0.72 dBs
Standard Deviation 1.253
|
-1.32 dBs
Standard Deviation 4.721
|
-0.23 dBs
Standard Deviation 0.213
|
-0.50 dBs
Standard Deviation 0.458
|
1.16 dBs
Standard Deviation 1.144
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 18: Non-Study Eye
|
0.18 dBs
Standard Deviation 0.191
|
1.24 dBs
Standard Deviation 1.265
|
-1.19 dBs
Standard Deviation 2.267
|
-0.33 dBs
Standard Deviation 0.412
|
-0.57 dBs
Standard Deviation 1.435
|
0.07 dBs
Standard Deviation 0.509
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 24: Study Eye
|
0.98 dBs
Standard Deviation 3.510
|
-2.37 dBs
Standard Deviation 1.225
|
-2.26 dBs
Standard Deviation 6.009
|
-0.40 dBs
Standard Deviation 0.382
|
-0.96 dBs
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
1.17 dBs
Standard Deviation 1.190
|
|
Part 1: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points Assessed by MAIA Microperimetry
Change From Baseline at Month 24: Non-Study Eye
|
0.24 dBs
Standard Deviation 0.153
|
0.75 dBs
Standard Deviation 1.427
|
-1.73 dBs
Standard Deviation 2.481
|
-0.37 dBs
Standard Deviation 0.427
|
-1.44 dBs
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
0.14 dBs
Standard Deviation 0.221
|
SECONDARY outcome
Timeframe: Baseline, Months 1, 3, 6, 9, 12, 18, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112).
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was reported as number of letters read correctly by the participants using the ETDRS Scale (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). An increase in the number of letters read correctly means that vision has improved. Here negative values indicate decline in BCVA.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Change From Baseline in Mean Best Corrected Visual Acuity (BCVA) Reported as Letters
Change From Baseline at Month 18: Study Eye
|
3.33 letters
Standard Deviation 3.786
|
-9.33 letters
Standard Deviation 28.919
|
-5.00 letters
Standard Deviation 8.544
|
3.00 letters
Standard Deviation 8.718
|
-2.00 letters
Standard Deviation 3.606
|
-3.33 letters
Standard Deviation 5.132
|
|
Part 1: Change From Baseline in Mean Best Corrected Visual Acuity (BCVA) Reported as Letters
Change From Baseline at Month 18: Non-Study Eye
|
1.33 letters
Standard Deviation 2.517
|
5.00 letters
Standard Deviation 7.810
|
-0.33 letters
Standard Deviation 5.508
|
-4.00 letters
Standard Deviation 6.245
|
0.00 letters
Standard Deviation 5.000
|
-0.33 letters
Standard Deviation 2.517
|
|
Part 1: Change From Baseline in Mean Best Corrected Visual Acuity (BCVA) Reported as Letters
Change From Baseline at Month 24: Study Eye
|
5.00 letters
Standard Deviation 7.000
|
-13.33 letters
Standard Deviation 32.747
|
-5.67 letters
Standard Deviation 6.110
|
-2.00 letters
Standard Deviation 15.588
|
-2.00 letters
Standard Deviation 5.292
|
-3.33 letters
Standard Deviation 3.215
|
|
Part 1: Change From Baseline in Mean Best Corrected Visual Acuity (BCVA) Reported as Letters
Change From Baseline at Month 24: Non-Study Eye
|
2.33 letters
Standard Deviation 4.509
|
2.00 letters
Standard Deviation 7.810
|
-2.00 letters
Standard Deviation 3.000
|
-3.67 letters
Standard Deviation 5.508
|
0.67 letters
Standard Deviation 0.577
|
-2.33 letters
Standard Deviation 1.528
|
|
Part 1: Change From Baseline in Mean Best Corrected Visual Acuity (BCVA) Reported as Letters
Change From Baseline at Month 6: Study Eye
|
3.67 letters
Standard Deviation 5.686
|
-3.67 letters
Standard Deviation 8.737
|
-0.67 letters
Standard Deviation 5.033
|
5.00 letters
Standard Deviation 1.000
|
-3.67 letters
Standard Deviation 3.786
|
0.33 letters
Standard Deviation 0.577
|
|
Part 1: Change From Baseline in Mean Best Corrected Visual Acuity (BCVA) Reported as Letters
Change From Baseline at Month 6: Non-Study Eye
|
3.67 letters
Standard Deviation 3.055
|
4.00 letters
Standard Deviation 4.359
|
-0.67 letters
Standard Deviation 1.528
|
-1.00 letters
Standard Deviation 7.211
|
-0.67 letters
Standard Deviation 4.726
|
-0.33 letters
Standard Deviation 3.215
|
|
Part 1: Change From Baseline in Mean Best Corrected Visual Acuity (BCVA) Reported as Letters
Change From Baseline at Month 3: Non-Study Eye
|
2.33 letters
Standard Deviation 2.309
|
4.67 letters
Standard Deviation 4.509
|
-0.33 letters
Standard Deviation 0.577
|
3.00 letters
Standard Deviation 1.000
|
1.67 letters
Standard Deviation 1.528
|
-1.67 letters
Standard Deviation 1.528
|
|
Part 1: Change From Baseline in Mean Best Corrected Visual Acuity (BCVA) Reported as Letters
Change From Baseline at Month 1: Non-Study Eye
|
0.33 letters
Standard Deviation 0.577
|
2.00 letters
Standard Deviation 4.583
|
-2.67 letters
Standard Deviation 1.155
|
3.00 letters
Standard Deviation 3.000
|
1.00 letters
Standard Deviation 4.359
|
1.00 letters
Standard Deviation 1.000
|
|
Part 1: Change From Baseline in Mean Best Corrected Visual Acuity (BCVA) Reported as Letters
Change From Baseline at Month 3: Study Eye
|
1.67 letters
Standard Deviation 4.726
|
0.33 letters
Standard Deviation 6.028
|
0.67 letters
Standard Deviation 6.506
|
6.33 letters
Standard Deviation 2.309
|
0.00 letters
Standard Deviation 3.606
|
0.67 letters
Standard Deviation 2.082
|
|
Part 1: Change From Baseline in Mean Best Corrected Visual Acuity (BCVA) Reported as Letters
Baseline: Study Eye
|
63.67 letters
Standard Deviation 20.551
|
70.67 letters
Standard Deviation 4.163
|
67.33 letters
Standard Deviation 15.044
|
27.67 letters
Standard Deviation 8.145
|
49.67 letters
Standard Deviation 9.452
|
64.33 letters
Standard Deviation 7.095
|
|
Part 1: Change From Baseline in Mean Best Corrected Visual Acuity (BCVA) Reported as Letters
Baseline: Non-Study Eye
|
62.67 letters
Standard Deviation 22.279
|
73.33 letters
Standard Deviation 4.163
|
75.00 letters
Standard Deviation 4.583
|
60.67 letters
Standard Deviation 2.082
|
57.33 letters
Standard Deviation 5.686
|
66.33 letters
Standard Deviation 2.517
|
|
Part 1: Change From Baseline in Mean Best Corrected Visual Acuity (BCVA) Reported as Letters
Change From Baseline at Month 1: Study Eye
|
-1.33 letters
Standard Deviation 6.506
|
-0.67 letters
Standard Deviation 4.041
|
-0.67 letters
Standard Deviation 10.693
|
3.67 letters
Standard Deviation 3.055
|
0.33 letters
Standard Deviation 2.517
|
-1.00 letters
Standard Deviation 1.732
|
|
Part 1: Change From Baseline in Mean Best Corrected Visual Acuity (BCVA) Reported as Letters
Change From Baseline at Month 9: Study Eye
|
4.00 letters
Standard Deviation 5.292
|
-3.67 letters
Standard Deviation 16.073
|
-2.33 letters
Standard Deviation 9.074
|
1.33 letters
Standard Deviation 4.619
|
-0.67 letters
Standard Deviation 0.577
|
1.33 letters
Standard Deviation 4.509
|
|
Part 1: Change From Baseline in Mean Best Corrected Visual Acuity (BCVA) Reported as Letters
Change From Baseline at Month 9: Non-Study Eye
|
3.00 letters
Standard Deviation 3.606
|
5.67 letters
Standard Deviation 8.622
|
2.00 letters
Standard Deviation 4.359
|
-5.00 letters
Standard Deviation 5.292
|
-0.67 letters
Standard Deviation 5.033
|
1.00 letters
Standard Deviation 1.000
|
|
Part 1: Change From Baseline in Mean Best Corrected Visual Acuity (BCVA) Reported as Letters
Change From Baseline at Month 12: Study Eye
|
4.33 letters
Standard Deviation 4.933
|
-15.00 letters
Standard Deviation 40.286
|
-2.33 letters
Standard Deviation 8.327
|
4.67 letters
Standard Deviation 4.509
|
-2.00 letters
Standard Deviation 3.464
|
0.67 letters
Standard Deviation 5.132
|
|
Part 1: Change From Baseline in Mean Best Corrected Visual Acuity (BCVA) Reported as Letters
Change From Baseline at Month 12: Non-Study Eye
|
2.00 letters
Standard Deviation 4.359
|
6.67 letters
Standard Deviation 6.429
|
1.00 letters
Standard Deviation 2.000
|
-1.67 letters
Standard Deviation 2.309
|
-0.33 letters
Standard Deviation 3.215
|
-0.33 letters
Standard Deviation 0.577
|
SECONDARY outcome
Timeframe: Baseline, Months 1, 3, 6, 9, 12, 18, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure.
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the participant using the ETDRS Scale (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). An increase in the number of letters read correctly means that vision has improved. Here negative values indicate decline in LLVA.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=4 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Change From Baseline in Mean Low Luminance Visual Acuity (LLVA) Reported as Letters
Change From Baseline at Month 6: Non-Study Eye
|
1.67 letters
Standard Deviation 2.887
|
5.33 letters
Standard Deviation 1.155
|
0.67 letters
Standard Deviation 3.215
|
—
|
—
|
8.00 letters
Standard Deviation 15.556
|
|
Part 1: Change From Baseline in Mean Low Luminance Visual Acuity (LLVA) Reported as Letters
Change From Baseline at Month 9: Study Eye
|
10.00 letters
Standard Deviation 6.557
|
-14.33 letters
Standard Deviation 37.820
|
4.33 letters
Standard Deviation 8.083
|
—
|
—
|
0.50 letters
Standard Deviation 4.950
|
|
Part 1: Change From Baseline in Mean Low Luminance Visual Acuity (LLVA) Reported as Letters
Change From Baseline at Month 9: Non-Study Eye
|
2.00 letters
Standard Deviation 4.359
|
2.00 letters
Standard Deviation 3.464
|
3.33 letters
Standard Deviation 2.309
|
—
|
—
|
0.50 letters
Standard Deviation 4.950
|
|
Part 1: Change From Baseline in Mean Low Luminance Visual Acuity (LLVA) Reported as Letters
Change From Baseline at Month 12: Non-Study Eye
|
6.67 letters
Standard Deviation 8.327
|
9.00 letters
Standard Deviation 4.359
|
4.00 letters
Standard Deviation 6.083
|
—
|
—
|
7.00 letters
Standard Deviation 9.899
|
|
Part 1: Change From Baseline in Mean Low Luminance Visual Acuity (LLVA) Reported as Letters
Change From Baseline at Month 18: Study Eye
|
10.67 letters
Standard Deviation 8.622
|
-12.33 letters
Standard Deviation 40.079
|
8.33 letters
Standard Deviation 5.508
|
—
|
—
|
6.50 letters
Standard Deviation 7.778
|
|
Part 1: Change From Baseline in Mean Low Luminance Visual Acuity (LLVA) Reported as Letters
Change From Baseline at Month 6: Study Eye
|
8.33 letters
Standard Deviation 7.234
|
-16.67 letters
Standard Deviation 35.810
|
7.33 letters
Standard Deviation 9.713
|
—
|
—
|
11.50 letters
Standard Deviation 7.778
|
|
Part 1: Change From Baseline in Mean Low Luminance Visual Acuity (LLVA) Reported as Letters
Change From Baseline at Month 12: Study Eye
|
16.00 letters
Standard Deviation 13.454
|
-11.33 letters
Standard Deviation 40.612
|
8.33 letters
Standard Deviation 11.590
|
—
|
—
|
3.50 letters
Standard Deviation 0.707
|
|
Part 1: Change From Baseline in Mean Low Luminance Visual Acuity (LLVA) Reported as Letters
Change From Baseline at Month 18: Non-Study Eye
|
2.33 letters
Standard Deviation 2.517
|
5.67 letters
Standard Deviation 4.726
|
-4.33 letters
Standard Deviation 7.234
|
—
|
—
|
9.00 letters
Standard Deviation 21.213
|
|
Part 1: Change From Baseline in Mean Low Luminance Visual Acuity (LLVA) Reported as Letters
Change From Baseline at Month 24: Study Eye
|
9.33 letters
Standard Deviation 14.295
|
-14.67 letters
Standard Deviation 38.371
|
-1.67 letters
Standard Deviation 6.506
|
—
|
—
|
3.00 letters
Standard Deviation 8.485
|
|
Part 1: Change From Baseline in Mean Low Luminance Visual Acuity (LLVA) Reported as Letters
Change From Baseline at Month 24: Non-Study Eye
|
0.67 letters
Standard Deviation 4.041
|
3.33 letters
Standard Deviation 3.512
|
-12.67 letters
Standard Deviation 11.547
|
—
|
—
|
5.50 letters
Standard Deviation 24.749
|
|
Part 1: Change From Baseline in Mean Low Luminance Visual Acuity (LLVA) Reported as Letters
Baseline: Study Eye
|
34.33 letters
Standard Deviation 29.939
|
58.00 letters
Standard Deviation 3.000
|
41.67 letters
Standard Deviation 34.646
|
—
|
—
|
41.00 letters
Standard Deviation 18.385
|
|
Part 1: Change From Baseline in Mean Low Luminance Visual Acuity (LLVA) Reported as Letters
Baseline: Non-Study Eye
|
37.67 letters
Standard Deviation 32.808
|
61.00 letters
Standard Deviation 2.646
|
57.33 letters
Standard Deviation 14.844
|
—
|
—
|
37.50 letters
Standard Deviation 24.749
|
|
Part 1: Change From Baseline in Mean Low Luminance Visual Acuity (LLVA) Reported as Letters
Change From Baseline at Month 1: Study Eye
|
0.33 letters
Standard Deviation 0.577
|
3.00 letters
Standard Deviation 5.292
|
4.67 letters
Standard Deviation 26.502
|
—
|
—
|
10.00 letters
Standard Deviation 9.899
|
|
Part 1: Change From Baseline in Mean Low Luminance Visual Acuity (LLVA) Reported as Letters
Change From Baseline at Month 1: Non-Study Eye
|
-0.33 letters
Standard Deviation 7.506
|
3.00 letters
Standard Deviation 5.196
|
-4.33 letters
Standard Deviation 7.572
|
—
|
—
|
10.00 letters
Standard Deviation 18.385
|
|
Part 1: Change From Baseline in Mean Low Luminance Visual Acuity (LLVA) Reported as Letters
Change From Baseline at Month 3: Study Eye
|
7.33 letters
Standard Deviation 6.658
|
-14.33 letters
Standard Deviation 38.214
|
-7.67 letters
Standard Deviation 10.263
|
—
|
—
|
14.00 letters
Standard Deviation 11.314
|
|
Part 1: Change From Baseline in Mean Low Luminance Visual Acuity (LLVA) Reported as Letters
Change From Baseline at Month 3: Non-Study Eye
|
1.00 letters
Standard Deviation 1.000
|
3.00 letters
Standard Deviation 4.583
|
2.00 letters
Standard Deviation 3.464
|
—
|
—
|
10.00 letters
Standard Deviation 16.971
|
SECONDARY outcome
Timeframe: Months 1, 3, 6, 9, 12, 18, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112).
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥15 letters increase from baseline for BCVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for BCVA
Month 18: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for BCVA
Month 18: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for BCVA
Month 24: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for BCVA
Month 1: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for BCVA
Month 1: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for BCVA
Month 3: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for BCVA
Month 3: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for BCVA
Month 6: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for BCVA
Month 6: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for BCVA
Month 9: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for BCVA
Month 9: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for BCVA
Month 12: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for BCVA
Month 12: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for BCVA
Month 24: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
SECONDARY outcome
Timeframe: Months 1, 3, 6, 9, 12, 18, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure.
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥15 letters increase from baseline for LLVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=4 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for LLVA
Month 3: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for LLVA
Month 1: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for LLVA
Month 1: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for LLVA
Month 3: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for LLVA
Month 6: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for LLVA
Month 6: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for LLVA
Month 9: Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for LLVA
Month 9: Non-Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for LLVA
Month 18: Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for LLVA
Month 18: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for LLVA
Month 12: Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for LLVA
Month 12: Non-Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for LLVA
Month 24: Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Increase From Baseline for LLVA
Month 24: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
SECONDARY outcome
Timeframe: Months 1, 3, 6, 9, 12, 18, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112).
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥10 letters increase from baseline for BCVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for BCVA
Month 1: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for BCVA
Month 18: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for BCVA
Month 24: Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for BCVA
Month 1: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for BCVA
Month 3: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for BCVA
Month 3: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for BCVA
Month 6: Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for BCVA
Month 6: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for BCVA
Month 9: Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for BCVA
Month 9: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for BCVA
Month 12: Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for BCVA
Month 12: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for BCVA
Month 18: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for BCVA
Month 24: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
SECONDARY outcome
Timeframe: Months 1, 3, 6, 9, 12, 18, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure.
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥10 letters increase from baseline for LLVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=4 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for LLVA
Month 3: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for LLVA
Month 9: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for LLVA
Month 12: Study Eye
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for LLVA
Month 12: Non-Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for LLVA
Month 1: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for LLVA
Month 1: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for LLVA
Month 3: Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for LLVA
Month 6: Study Eye
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for LLVA
Month 6: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for LLVA
Month 9: Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for LLVA
Month 18: Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for LLVA
Month 18: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for LLVA
Month 24: Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Increase From Baseline for LLVA
Month 24: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
SECONDARY outcome
Timeframe: Months 1, 3, 6, 9, 12, 18, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112).
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters increase from baseline for BCVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for BCVA
Month 1: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for BCVA
Month 1: Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for BCVA
Month 3: Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for BCVA
Month 3: Non-Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for BCVA
Month 6: Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for BCVA
Month 6: Non-Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.03 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for BCVA
Month 9: Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for BCVA
Month 9: Non-Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for BCVA
Month 12: Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for BCVA
Month 12: Non-Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for BCVA
Month 18: Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for BCVA
Month 18: Non-Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for BCVA
Month 24: Study Eye
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for BCVA
Month 24: Non-Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
SECONDARY outcome
Timeframe: Months 1, 3, 6, 9, 12, 18, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure.
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters increase from baseline for LLVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=4 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for LLVA
Month 24: Non-Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for LLVA
Month 18: Study Eye
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for LLVA
Month 1: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for LLVA
Month 1: Non-Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for LLVA
Month 3: Study Eye
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
100.0 percentage of eyes
Interval 15.8 to 100.0
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for LLVA
Month 3: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for LLVA
Month 6: Study Eye
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
—
|
—
|
100.0 percentage of eyes
Interval 15.8 to 100.0
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for LLVA
Month 6: Non-Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for LLVA
Month 9: Study Eye
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for LLVA
Month 9: Non-Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for LLVA
Month 12: Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for LLVA
Month 12: Non-Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for LLVA
Month 18: Non-Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Increase From Baseline for LLVA
Month 24: Study Eye
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
SECONDARY outcome
Timeframe: Months 1, 3, 6, 9, 12, 18, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112).
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥15 letters loss from baseline for BCVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 1: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 1: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 3: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 3: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 6: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 6: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 9: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 9: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 12: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 12: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 18: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 18: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 24: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 24: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
SECONDARY outcome
Timeframe: Months 1, 3, 6, 9, 12, 18, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure.
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥15 letters loss from baseline for LLVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=4 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
Month 1: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
Month 1: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
Month 3: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
Month 3: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
Month 6: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
Month 6: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
Month 9: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
Month 9: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
Month 12: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
Month 12: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
Month 18: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
Month 18: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
Month 24: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
Month 24: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
SECONDARY outcome
Timeframe: Months 1, 3, 6, 9, 12, 18, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112).
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥10 letters loss from baseline for BCVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=3 Participants
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 1: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 1: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 3: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 3: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 6: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 6: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 9: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 9: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 12: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 12: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 18: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 18: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 24: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 24: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
SECONDARY outcome
Timeframe: Months 1, 3, 6, 9, 12, 18, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure.
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥10 letters loss from baseline for LLVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=4 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
Month 1: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
Month 1: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
Month 3: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
Month 3: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
Month 6: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
Month 6: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
Month 9: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
Month 9: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
Month 12: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
Month 12: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
Month 18: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
Month 18: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
Month 24: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
Month 24: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
SECONDARY outcome
Timeframe: Months 1, 3, 6, 9, 12, 18, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112).
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters loss from baseline for BCVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 3: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 24: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
33.3 percentage of eyes
Interval 0.8 to 99.2
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 1: Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 1: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 3: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 6: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 6: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 9: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 9: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 12: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 12: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 18: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 18: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
66.7 percentage of eyes
Interval 9.4 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 24: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
SECONDARY outcome
Timeframe: Months 1, 3, 6, 9, 12, 18, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure.
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters loss from baseline for LLVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=4 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
Month 24: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
Month 1: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
Month 1: Non-Study Eye
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.00 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
Month 3: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
Month 3: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
Month 6: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
Month 6: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
Month 9: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
Month 9: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
Month 12: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
Month 12: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
Month 18: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
Month 18: Non-Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
Month 24: Study Eye
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 84.2
|
SECONDARY outcome
Timeframe: Months 1, 3, 6, 9, 12, 18, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112).
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). An increase in the number of letters read correctly means that vision has improved. Percentage of eyes with a change from baseline of ≥ -5 letters for BCVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for BCVA
Month 1: Non-Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for BCVA
Month 24: Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for BCVA
Month 24: Non-Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for BCVA
Month 9: Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for BCVA
Month 1: Study Eye
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for BCVA
Month 3: Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for BCVA
Month 3: Non-Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for BCVA
Month 6: Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for BCVA
Month 6: Non-Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for BCVA
Month 9: Non-Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for BCVA
Month 12: Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for BCVA
Month 12: Non-Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for BCVA
Month 18: Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for BCVA
Month 18: Non-Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
SECONDARY outcome
Timeframe: Months 1, 3, 6, 9, 12, 18, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure.
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). An increase in the number of letters read correctly means that vision has improved. Percentage of eyes with a change from baseline of ≥ -5 letters for LLVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=4 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for LLVA
Month 9: Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
—
|
—
|
100.0 percentage of eyes
Interval 15.8 to 100.0
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for LLVA
Month 18: Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
—
|
—
|
100.0 percentage of eyes
Interval 15.8 to 100.0
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for LLVA
Month 24: Non-Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
0.0 percentage of eyes
Interval 0.0 to 70.8
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for LLVA
Month 12: Non-Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
—
|
—
|
100.0 percentage of eyes
Interval 15.8 to 100.0
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for LLVA
Month 1: Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
—
|
—
|
100.0 percentage of eyes
Interval 15.8 to 100.0
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for LLVA
Month 1: Non-Study Eye
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
—
|
—
|
100.0 percentage of eyes
Interval 15.8 to 100.0
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for LLVA
Month 3: Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
—
|
—
|
100.0 percentage of eyes
Interval 15.8 to 100.0
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for LLVA
Month 3: Non-Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
—
|
—
|
100.0 percentage of eyes
Interval 15.8 to 100.0
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for LLVA
Month 6: Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
—
|
—
|
100.0 percentage of eyes
Interval 15.8 to 100.0
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for LLVA
Month 6: Non-Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
—
|
—
|
100.0 percentage of eyes
Interval 15.8 to 100.0
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for LLVA
Month 9: Non-Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
—
|
—
|
100.0 percentage of eyes
Interval 15.8 to 100.0
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for LLVA
Month 12: Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
—
|
—
|
100.0 percentage of eyes
Interval 15.8 to 100.0
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for LLVA
Month 18: Non-Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
33.3 percentage of eyes
Interval 0.8 to 90.6
|
—
|
—
|
50.0 percentage of eyes
Interval 1.3 to 98.7
|
|
Part 1: Percentage of Eyes With Change From Baseline > -5 Letters for LLVA
Month 24: Study Eye
|
100.0 percentage of eyes
Interval 29.2 to 100.0
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
66.7 percentage of eyes
Interval 9.4 to 99.2
|
—
|
—
|
100.0 percentage of eyes
Interval 15.8 to 100.0
|
SECONDARY outcome
Timeframe: Baseline, Months 1, 3, 6, 9, 12, 18, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Spectral Domain Optical Coherence Tomography (SD-OCT) was used to assess change in central ellipsoid area. The measurements were taken after dilation of the participant's pupil. A negative change from baseline indicates a decline in central ellipsoid area.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Change From Baseline in Central Ellipsoid Area
Baseline: Study Eye
|
0.193 square millimeters (mm^2)
Standard Deviation 0.1686
|
8.327 square millimeters (mm^2)
Standard Deviation 13.8600
|
3.107 square millimeters (mm^2)
Standard Deviation 5.2001
|
0.140 square millimeters (mm^2)
Standard Deviation 0.1637
|
2.750 square millimeters (mm^2)
Standard Deviation 4.7631
|
0.137 square millimeters (mm^2)
Standard Deviation 0.1582
|
|
Part 1: Change From Baseline in Central Ellipsoid Area
Baseline: Non-Study Eye
|
0.465 square millimeters (mm^2)
Standard Deviation 0.1061
|
14.307 square millimeters (mm^2)
Standard Deviation 24.1914
|
5.257 square millimeters (mm^2)
Standard Deviation 8.8720
|
0.130 square millimeters (mm^2)
Standard Deviation 0.0985
|
2.313 square millimeters (mm^2)
Standard Deviation 3.7500
|
0.093 square millimeters (mm^2)
Standard Deviation 0.0814
|
|
Part 1: Change From Baseline in Central Ellipsoid Area
Change From Baseline at Month 6: Study Eye
|
-0.070 square millimeters (mm^2)
Standard Deviation 0.0624
|
-4.847 square millimeters (mm^2)
Standard Deviation 8.1176
|
-0.055 square millimeters (mm^2)
Standard Deviation 0.0778
|
-0.120 square millimeters (mm^2)
Standard Deviation 0.1375
|
-0.527 square millimeters (mm^2)
Standard Deviation 0.9122
|
-0.113 square millimeters (mm^2)
Standard Deviation 0.1206
|
|
Part 1: Change From Baseline in Central Ellipsoid Area
Change From Baseline at Month 6: Non-Study Eye
|
-0.120 square millimeters (mm^2)
Standard Deviation 0.0424
|
-0.983 square millimeters (mm^2)
Standard Deviation 1.7747
|
-0.050 square millimeters (mm^2)
Standard Deviation 0.0707
|
-0.093 square millimeters (mm^2)
Standard Deviation 0.0404
|
-0.410 square millimeters (mm^2)
Standard Deviation 0.4951
|
-0.060 square millimeters (mm^2)
Standard Deviation 0.0529
|
|
Part 1: Change From Baseline in Central Ellipsoid Area
Change From Baseline at Month 12: Study Eye
|
-0.053 square millimeters (mm^2)
Standard Deviation 0.0551
|
-5.623 square millimeters (mm^2)
Standard Deviation 9.4975
|
-3.007 square millimeters (mm^2)
Standard Deviation 5.1386
|
-0.130 square millimeters (mm^2)
Standard Deviation 0.1473
|
-0.560 square millimeters (mm^2)
Standard Deviation 0.9699
|
-0.117 square millimeters (mm^2)
Standard Deviation 0.1258
|
|
Part 1: Change From Baseline in Central Ellipsoid Area
Change From Baseline at Month 18: Non-Study Eye
|
-0.115 square millimeters (mm^2)
Standard Deviation 0.0919
|
-1.107 square millimeters (mm^2)
Standard Deviation 2.0124
|
0.590 square millimeters (mm^2)
Standard Deviation 1.1364
|
0.1528 square millimeters (mm^2)
Standard Deviation 0.0709
|
-0.450 square millimeters (mm^2)
Standard Deviation 0.5408
|
-0.027 square millimeters (mm^2)
Standard Deviation 0.1201
|
|
Part 1: Change From Baseline in Central Ellipsoid Area
Change From Baseline at Month 1: Study Eye
|
-0.050 square millimeters (mm^2)
Standard Deviation 0.0458
|
-1.360 square millimeters (mm^2)
Standard Deviation 2.2863
|
-1.310 square millimeters (mm^2)
Standard Deviation 2.2258
|
-0.077 square millimeters (mm^2)
Standard Deviation 0.1159
|
-0.493 square millimeters (mm^2)
Standard Deviation 0.8545
|
-0.103 square millimeters (mm^2)
Standard Deviation 0.1050
|
|
Part 1: Change From Baseline in Central Ellipsoid Area
Change From Baseline at Month 1: Non-Study Eye
|
-0.080 square millimeters (mm^2)
Standard Deviation 0.0566
|
-0.410 square millimeters (mm^2)
Standard Deviation 0.7645
|
0.873 square millimeters (mm^2)
Standard Deviation 1.5824
|
-0.060 square millimeters (mm^2)
Standard Deviation 0.0265
|
-0.383 square millimeters (mm^2)
Standard Deviation 0.4508
|
-0.020 square millimeters (mm^2)
Standard Deviation 0.0693
|
|
Part 1: Change From Baseline in Central Ellipsoid Area
Change From Baseline at Month 3: Study Eye
|
-0.060 square millimeters (mm^2)
Standard Deviation 0.0529
|
-2.255 square millimeters (mm^2)
Standard Deviation 3.0335
|
-2.960 square millimeters (mm^2)
Standard Deviation 5.0319
|
-0.100 square millimeters (mm^2)
Standard Deviation 0.1249
|
-0.560 square millimeters (mm^2)
Standard Deviation 0.9699
|
-0.110 square millimeters (mm^2)
Standard Deviation 0.1153
|
|
Part 1: Change From Baseline in Central Ellipsoid Area
Change From Baseline at Month 3: Non-Study Eye
|
-0.095 square millimeters (mm^2)
Standard Deviation 0.0495
|
-0.407 square millimeters (mm^2)
Standard Deviation 0.7778
|
-0.040 square millimeters (mm^2)
Standard Deviation 0.0566
|
-0.093 square millimeters (mm^2)
Standard Deviation 0.0404
|
-0.407 square millimeters (mm^2)
Standard Deviation 0.4895
|
-0.043 square millimeters (mm^2)
Standard Deviation 0.0379
|
|
Part 1: Change From Baseline in Central Ellipsoid Area
Change From Baseline at Month 9: Study Eye
|
-0.063 square millimeters (mm^2)
Standard Deviation 0.0551
|
-5.640 square millimeters (mm^2)
Standard Deviation 9.4830
|
-2.960 square millimeters (mm^2)
Standard Deviation 5.0664
|
-0.127 square millimeters (mm^2)
Standard Deviation 0.1419
|
-0.540 square millimeters (mm^2)
Standard Deviation 0.9353
|
-0.117 square millimeters (mm^2)
Standard Deviation 0.1258
|
|
Part 1: Change From Baseline in Central Ellipsoid Area
Change From Baseline at Month 9: Non-Study Eye
|
-0.120 square millimeters (mm^2)
Standard Deviation 0.0141
|
-1.100 square millimeters (mm^2)
Standard Deviation 1.9504
|
-0.050 square millimeters (mm^2)
Standard Deviation 0.0707
|
-0.097 square millimeters (mm^2)
Standard Deviation 0.0451
|
-0.437 square millimeters (mm^2)
Standard Deviation 0.5326
|
-0.063 square millimeters (mm^2)
Standard Deviation 0.0569
|
|
Part 1: Change From Baseline in Central Ellipsoid Area
Change From Baseline at Month 12: Non-Study Eye
|
-0.120 square millimeters (mm^2)
Standard Deviation 0.0424
|
-1.010 square millimeters (mm^2)
Standard Deviation 2.0313
|
0.997 square millimeters (mm^2)
Standard Deviation 1.8312
|
-0.097 square millimeters (mm^2)
Standard Deviation 0.0451
|
-0.447 square millimeters (mm^2)
Standard Deviation 0.5353
|
-0.033 square millimeters (mm^2)
Standard Deviation 0.1266
|
|
Part 1: Change From Baseline in Central Ellipsoid Area
Change From Baseline at Month 18: Study Eye
|
0.027 square millimeters (mm^2)
Standard Deviation 0.1617
|
-5.633 square millimeters (mm^2)
Standard Deviation 9.4975
|
-2.993 square millimeters (mm^2)
Standard Deviation 5.1155
|
-0.133 square millimeters (mm^2)
Standard Deviation 0.1528
|
-0.567 square millimeters (mm^2)
Standard Deviation 0.9815
|
-0.137 square millimeters (mm^2)
Standard Deviation 0.1582
|
|
Part 1: Change From Baseline in Central Ellipsoid Area
Change From Baseline at Month 24: Study Eye
|
0.010 square millimeters (mm^2)
Standard Deviation 0.1552
|
-5.657 square millimeters (mm^2)
Standard Deviation 9.5292
|
-3.010 square millimeters (mm^2)
Standard Deviation 5.1357
|
-0.133 square millimeters (mm^2)
Standard Deviation 0.1528
|
-0.573 square millimeters (mm^2)
Standard Deviation 0.9930
|
-0.137 square millimeters (mm^2)
Standard Deviation 0.1582
|
|
Part 1: Change From Baseline in Central Ellipsoid Area
Change From Baseline at Month 24: Non-Study Eye
|
-0.150 square millimeters (mm^2)
Standard Deviation 0.0283
|
-1.163 square millimeters (mm^2)
Standard Deviation 2.0063
|
0.367 square millimeters (mm^2)
Standard Deviation 0.7505
|
-0.117 square millimeters (mm^2)
Standard Deviation 0.0764
|
-0.443 square millimeters (mm^2)
Standard Deviation 0.5297
|
-0.060 square millimeters (mm^2)
Standard Deviation 0.0794
|
SECONDARY outcome
Timeframe: Baseline, Months 1, 3, 6, 9, 12, 18, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
SD-OCT was used to assess change in central horizontal ellipsoid width. The measurements were taken after dilation of the participant's pupil. A negative change from baseline indicates a decline in central horizontal ellipsoid width.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Change From Baseline in Central Horizontal Ellipsoid Width
Change From Baseline at Month 9: Non-Study Eye
|
-202.50 Microns
Standard Deviation 4.950
|
-81.67 Microns
Standard Deviation 217.721
|
-124.00 Microns
Standard Deviation 175.362
|
-175.00 Microns
Standard Deviation 39.585
|
-348.00 Microns
Standard Deviation 602.754
|
-77.33 Microns
Standard Deviation 79.053
|
|
Part 1: Change From Baseline in Central Horizontal Ellipsoid Width
Change From Baseline at Month 12: Study Eye
|
-106.33 Microns
Standard Deviation 132.666
|
-1055.33 Microns
Standard Deviation 1394.128
|
-463.00 Microns
Standard Deviation 537.199
|
-130.00 Microns
Standard Deviation 125.300
|
-238.33 Microns
Standard Deviation 412.805
|
-217.00 Microns
Standard Deviation 225.980
|
|
Part 1: Change From Baseline in Central Horizontal Ellipsoid Width
Change From Baseline at Month 9: Study Eye
|
-149.00 Microns
Standard Deviation 131.936
|
-1096.33 Microns
Standard Deviation 1343.289
|
-441.00 Microns
Standard Deviation 505.720
|
-127.00 Microns
Standard Deviation 121.025
|
-321.33 Microns
Standard Deviation 556.566
|
-178.33 Microns
Standard Deviation 168.548
|
|
Part 1: Change From Baseline in Central Horizontal Ellipsoid Width
Change From Baseline at Month 24: Non-Study Eye
|
-254.50 Microns
Standard Deviation 7.778
|
-159.67 Microns
Standard Deviation 265.038
|
1065.67 Microns
Standard Deviation 2074.136
|
-329.33 Microns
Standard Deviation 235.434
|
-358.00 Microns
Standard Deviation 620.074
|
-145.67 Microns
Standard Deviation 162.543
|
|
Part 1: Change From Baseline in Central Horizontal Ellipsoid Width
Baseline: Study Eye
|
462.33 Microns
Standard Deviation 400.775
|
2411.33 Microns
Standard Deviation 3048.253
|
745.67 Microns
Standard Deviation 774.448
|
162.67 Microns
Standard Deviation 175.104
|
1375.33 Microns
Standard Deviation 2382.147
|
248.00 Microns
Standard Deviation 275.158
|
|
Part 1: Change From Baseline in Central Horizontal Ellipsoid Width
Baseline: Non-Study Eye
|
792.00 Microns
Standard Deviation 300.409
|
3341.00 Microns
Standard Deviation 4556.473
|
937.67 Microns
Standard Deviation 1088.262
|
355.67 Microns
Standard Deviation 378
|
1383.67 Microns
Standard Deviation 396.581
|
250.00 Microns
Standard Deviation 33.139
|
|
Part 1: Change From Baseline in Central Horizontal Ellipsoid Width
Change From Baseline at Month 1: Study Eye
|
-26.33 Microns
Standard Deviation 24.007
|
4556.473 Microns
Standard Deviation 248.605
|
88.67 Microns
Standard Deviation 422.044
|
-56.33 Microns
Standard Deviation 73.894
|
-311.00 Microns
Standard Deviation 538.668
|
-174.00 Microns
Standard Deviation 162.567
|
|
Part 1: Change From Baseline in Central Horizontal Ellipsoid Width
Change From Baseline at Month 1: Non-Study Eye
|
-56.00 Microns
Standard Deviation 63.640
|
-14.00 Microns
Standard Deviation 113.331
|
977.33 Microns
Standard Deviation 1814.500
|
-62.33 Microns
Standard Deviation 40.216
|
-321.67 Microns
Standard Deviation 557.143
|
47.33 Microns
Standard Deviation 226.509
|
|
Part 1: Change From Baseline in Central Horizontal Ellipsoid Width
Change From Baseline at Month 3: Study Eye
|
-89.33 Microns
Standard Deviation 125.644
|
-369.00 Microns
Standard Deviation 271.070
|
-453.33 Microns
Standard Deviation 554.795
|
-73.00 Microns
Standard Deviation 70.193
|
-318.00 Microns
Standard Deviation 550.792
|
-174.33 Microns
Standard Deviation 163.022
|
|
Part 1: Change From Baseline in Central Horizontal Ellipsoid Width
Change From Baseline at Month 3: Non-Study Eye
|
-151.00 Microns
Standard Deviation 15.556
|
-19.00 Microns
Standard Deviation 123.503
|
1008.33 Microns
Standard Deviation 1869.924
|
-149.00 Microns
Standard Deviation 80.988
|
-333.33 Microns
Standard Deviation 577.350
|
-60.67 Microns
Standard Deviation 78.258
|
|
Part 1: Change From Baseline in Central Horizontal Ellipsoid Width
Change From Baseline at Month 6: Study Eye
|
-146.67 Microns
Standard Deviation 129.454
|
-1070.67 Microns
Standard Deviation 1365.685
|
-461.33 Microns
Standard Deviation 553.453
|
-115.67 Microns
Standard Deviation 105.624
|
-318.67 Microns
Standard Deviation 551.947
|
-175.67 Microns
Standard Deviation 164.852
|
|
Part 1: Change From Baseline in Central Horizontal Ellipsoid Width
Change From Baseline at Month 6: Non-Study Eye
|
-195.50 Microns
Standard Deviation 6.364
|
-20.00 Microns
Standard Deviation 144.503
|
-108.50 Microns
Standard Deviation 153.442
|
-158.67 Microns
Standard Deviation 65.033
|
-347.00 Microns
Standard Deviation 601.022
|
-76.33 Microns
Standard Deviation 79.135
|
|
Part 1: Change From Baseline in Central Horizontal Ellipsoid Width
Change From Baseline at Month 12: Non-Study Eye
|
-113.50 Microns
Standard Deviation 47.376
|
-143.00 Microns
Standard Deviation 221.007
|
1108.00 Microns
Standard Deviation 2145.532
|
-181.67 Microns
Standard Deviation 30.665
|
-349.33 Microns
Standard Deviation 605.063
|
-35.67 Microns
Standard Deviation 255.895
|
|
Part 1: Change From Baseline in Central Horizontal Ellipsoid Width
Change From Baseline at Month 18: Study Eye
|
21.67 Microns
Standard Deviation 332.031
|
-1059.67 Microns
Standard Deviation 1438.362
|
-461.67 Microns
Standard Deviation 530.381
|
-131.00 Microns
Standard Deviation 126.740
|
-239.33 Microns
Standard Deviation 414.537
|
-248.00 Microns
Standard Deviation 275.158
|
|
Part 1: Change From Baseline in Central Horizontal Ellipsoid Width
Change From Baseline at Month 18: Non-Study Eye
|
-188.00 Microns
Standard Deviation 65.054
|
-113.00 Microns
Standard Deviation 242.736
|
1078.67 Microns
Standard Deviation 2094.819
|
-316.67 Microns
Standard Deviation 213.601
|
-354.67 Microns
Standard Deviation 614.301
|
-168.67 Microns
Standard Deviation 161.122
|
|
Part 1: Change From Baseline in Central Horizontal Ellipsoid Width
Change From Baseline at Month 24: Study Eye
|
-43.33 Microns
Standard Deviation 243.904
|
-1162.00 Microns
Standard Deviation 1352.050
|
-465.67 Microns
Standard Deviation 587.699
|
-131.33 Microns
Standard Deviation 127.222
|
-242.33 Microns
Standard Deviation 419.734
|
-248.00 Microns
Standard Deviation 275.158
|
SECONDARY outcome
Timeframe: Baseline, Months 1, 3, 6, 9, 12, 18, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Fundus Autofluoroscence was used to assess the total area of preserved autofluoroscence. Areas of preserved AF were identified as well-demarcated regions of relative hyper autofluorescence (hyper AF) compared with the background areas of surrounding atrophy. A negative change from baseline indicates a decline in total area of preserved autofluoroscence.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=2 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=2 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Total Area of Preserved Autofluoroscence
Baseline: Study Eye
|
—
|
—
|
—
|
27.050 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
—
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Total Area of Preserved Autofluoroscence
Baseline: Non-Study Eye
|
—
|
—
|
—
|
22.910 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
50.640 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Total Area of Preserved Autofluoroscence
Change From Baseline at Month 1: Study Eye
|
—
|
—
|
—
|
-1.820 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
—
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Total Area of Preserved Autofluoroscence
Change From Baseline at Month 1: Non-Study Eye
|
—
|
—
|
—
|
-2.420 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
-8.620 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Total Area of Preserved Autofluoroscence
Change From Baseline at Month 3: Study Eye
|
—
|
—
|
—
|
-2.940 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
—
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Total Area of Preserved Autofluoroscence
Change From Baseline at Month 3: Non-Study Eye
|
—
|
—
|
—
|
-2.650 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
-5.150 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Total Area of Preserved Autofluoroscence
Change From Baseline at Month 6: Study Eye
|
—
|
—
|
—
|
-3.460 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
—
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Total Area of Preserved Autofluoroscence
Change From Baseline at Month 6: Non-Study Eye
|
—
|
—
|
—
|
-3.050 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
-6.530 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Total Area of Preserved Autofluoroscence
Change From Baseline at Month 9: Study Eye
|
—
|
—
|
—
|
-3.470 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
—
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Total Area of Preserved Autofluoroscence
Change From Baseline at Month 9: Non-Study Eye
|
—
|
—
|
—
|
-3.100 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
-9.130 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Total Area of Preserved Autofluoroscence
Change From Baseline at Month 12: Study Eye
|
—
|
—
|
—
|
-3.640 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
—
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Total Area of Preserved Autofluoroscence
Change From Baseline at Month 12: Non-Study Eye
|
—
|
—
|
—
|
-3.760 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
-9.220 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Total Area of Preserved Autofluoroscence
Change From Baseline at Month 18: Study Eye
|
—
|
—
|
—
|
-3.670 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
—
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Total Area of Preserved Autofluoroscence
Change From Baseline at Month 18: Non-Study Eye
|
—
|
—
|
—
|
-3.830 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
-11.700 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Total Area of Preserved Autofluoroscence
Change From Baseline at Month 24: Study Eye
|
—
|
—
|
—
|
-3.740 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
—
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Total Area of Preserved Autofluoroscence
Change From Baseline at Month 24: Non-Study Eye
|
—
|
—
|
—
|
-4.120 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline, Months 1, 3, 6, 9, 12, 18, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Fundus Autofluoroscence was used to assess the distance from FC to nearest border of preserved autofluoroscence. A negative change from baseline indicates a decline in the total area of preserved autofluoroscence.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=2 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=2 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=2 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=4 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=2 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=2 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Distance From Foveal Center (FC) to Nearest Border of Preserved Autofluoroscence
Baseline: Non-Study Eye
|
369.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
2816.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
4047.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
2609.00 mm^2
Standard Deviation 386.080
|
-24.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
3052.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Distance From Foveal Center (FC) to Nearest Border of Preserved Autofluoroscence
Change From Baseline at Month 6: Study Eye
|
-93.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-122.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
-128.50 mm^2
Standard Deviation 54.447
|
-24.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-179.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Distance From Foveal Center (FC) to Nearest Border of Preserved Autofluoroscence
Change From Baseline at Month 9: Study Eye
|
-94.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-140.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
-140.00 mm^2
Standard Deviation 41.012
|
-35.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-281.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Distance From Foveal Center (FC) to Nearest Border of Preserved Autofluoroscence
Change From Baseline at Month 24: Study Eye
|
-125.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-1293.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
-1501.00 mm^2
Standard Deviation 1820.093
|
-69.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-226.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Distance From Foveal Center (FC) to Nearest Border of Preserved Autofluoroscence
Baseline: Study Eye
|
361.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
2853.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
2394.50 mm^2
Standard Deviation 665.387
|
-39.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
3018.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Distance From Foveal Center (FC) to Nearest Border of Preserved Autofluoroscence
Change From Baseline at Month 1: Study Eye
|
-14.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-5.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
-33.00 mm^2
Standard Deviation 5.657
|
-14.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-52.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Distance From Foveal Center (FC) to Nearest Border of Preserved Autofluoroscence
Change From Baseline at Month 1: Non-Study Eye
|
-18.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-12.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-3.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-255.50 mm^2
Standard Deviation 297.692
|
-19.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-281.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Distance From Foveal Center (FC) to Nearest Border of Preserved Autofluoroscence
Change From Baseline at Month 3: Study Eye
|
-89.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-104.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
-87.00 mm^2
Standard Deviation 24.042
|
-16.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-138.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Distance From Foveal Center (FC) to Nearest Border of Preserved Autofluoroscence
Change From Baseline at Month 3: Non-Study Eye
|
-22.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-93.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-21.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-276.50 mm^2
Standard Deviation 324.562
|
-30.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-375.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Distance From Foveal Center (FC) to Nearest Border of Preserved Autofluoroscence
Change From Baseline at Month 6: Non-Study Eye
|
-36.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-102.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
-297.00 mm^2
Standard Deviation 349.311
|
-41.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-462.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Distance From Foveal Center (FC) to Nearest Border of Preserved Autofluoroscence
Change From Baseline at Month 9: Non-Study Eye
|
-38.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
92.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
-310.50 mm^2
Standard Deviation 333.047
|
-58.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-413.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Distance From Foveal Center (FC) to Nearest Border of Preserved Autofluoroscence
Change From Baseline at Month 12: Study Eye
|
-101.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-708.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
-1489.50 mm^2
Standard Deviation 1829.285
|
—
|
-282.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Distance From Foveal Center (FC) to Nearest Border of Preserved Autofluoroscence
Change From Baseline at Month 12: Non-Study Eye
|
-39.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
89.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
-353.50 mm^2
Standard Deviation 318.905
|
—
|
-422.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Distance From Foveal Center (FC) to Nearest Border of Preserved Autofluoroscence
Change From Baseline at Month 18: Study Eye
|
-123.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-1278.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
-1493.00 mm^2
Standard Deviation 1829.992
|
-55.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-310.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Distance From Foveal Center (FC) to Nearest Border of Preserved Autofluoroscence
Change From Baseline at Month 18: Non-Study Eye
|
-11.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
65.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
-358.00 mm^2
Standard Deviation 318.198
|
-86.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-425.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
|
Part 1: Change From Baseline in Fundus Autofluoroscence- Mean Distance From Foveal Center (FC) to Nearest Border of Preserved Autofluoroscence
Change From Baseline at Month 24: Non-Study Eye
|
-13.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
62.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
-391.00 mm^2
Standard Deviation 301.227
|
-91.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-2646.00 mm^2
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
SECONDARY outcome
Timeframe: Baseline, Months 6, 12, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Visual field testing was performed to assess the volume of 30-degree hill vision, reported as dBs. Reliability Factor (RF)=number of false positive responses + number of false negative responses/number of false positive presentations + number of false negative presentations\*100. If there are 0 responses, then RF value=0. RFpositive=number of false positive responses/number of false positive presentations\*100. If RF≤ 20% measurement is considered reliable. If 20% \< RF ≤ 25% and RFpositive ≤ 10% measurement is also considered reliable. Otherwise if 20% \< RF ≤ 25% and RFpositive \> 10%, or RF \> 25%, measurement is not reliable. Only reliable measurements were included for analysis of this outcome measure. Here negative values indicate decline in volume of 30-degree hill vision.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=2 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=2 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Change From Baseline in Mean Volume of 30-Degree Hill of Vision
Change From Baseline at Month 24: Study Eye
|
—
|
-1.89 dBs
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-3.08 dBs
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
—
|
—
|
|
Part 1: Change From Baseline in Mean Volume of 30-Degree Hill of Vision
Baseline: Study Eye
|
—
|
2.73 dBs
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
5.07 dBs
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
—
|
—
|
|
Part 1: Change From Baseline in Mean Volume of 30-Degree Hill of Vision
Baseline: Non-Study Eye
|
—
|
—
|
5.17 dBs
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
—
|
—
|
|
Part 1: Change From Baseline in Mean Volume of 30-Degree Hill of Vision
Change From Baseline at Month 6: Study Eye
|
—
|
—
|
-2.14 dBs
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
—
|
—
|
|
Part 1: Change From Baseline in Mean Volume of 30-Degree Hill of Vision
Change From Baseline at Month 6: Non-Study Eye
|
—
|
—
|
-1.10 dBs
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
—
|
—
|
|
Part 1: Change From Baseline in Mean Volume of 30-Degree Hill of Vision
Change From Baseline at Month 12: Study Eye
|
—
|
0.33 dBs
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-2.80 dBs
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
—
|
—
|
|
Part 1: Change From Baseline in Mean Volume of 30-Degree Hill of Vision
Change From Baseline at Month 12: Non-Study Eye
|
—
|
—
|
-1.02 dBs
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
—
|
—
|
|
Part 1: Change From Baseline in Mean Volume of 30-Degree Hill of Vision
Change From Baseline at Month 24: Non-Study Eye
|
—
|
—
|
-2.11 dBs
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline, Months 6, 12, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Visual field testing was performed to assess the volume of full field of hill vision, reported as dBs. RF =number of false positive responses + number of false negative responses/number of false positive presentations + number of false negative presentations\*100. If there are 0 responses, then RF value=0. RFpositive=number of false positive responses/number of false positive presentations\*100. If RF≤ 20% measurement is considered reliable. If 20% \< RF ≤ 25% and RFpositive ≤ 10% measurement is also considered reliable. Otherwise if 20% \< RF ≤ 25% and RFpositive \> 10%, or RF \> 25%, measurement is not reliable. Only reliable measurements were included for analysis of this outcome measure. Here negative values indicate decline in volume of 30-degree hill vision.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=2 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=2 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Change From Baseline in Mean Volume of Full Field Hill of Vision
Change From Baseline at Month 12: Study Eye
|
—
|
1.29 dBs
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-2.98 dBs
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
—
|
—
|
|
Part 1: Change From Baseline in Mean Volume of Full Field Hill of Vision
Change From Baseline at Month 24: Study Eye
|
—
|
-6.28 dBs
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
-5.36 dBs
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
—
|
—
|
|
Part 1: Change From Baseline in Mean Volume of Full Field Hill of Vision
Change From Baseline at Month 24: Non-Study Eye
|
—
|
—
|
-7.87 dBs
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
—
|
—
|
|
Part 1: Change From Baseline in Mean Volume of Full Field Hill of Vision
Baseline: Study Eye
|
—
|
15.77 dBs
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
18.31 dBs
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
—
|
—
|
|
Part 1: Change From Baseline in Mean Volume of Full Field Hill of Vision
Baseline: Non-Study Eye
|
—
|
—
|
23.41 dBs
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
—
|
—
|
|
Part 1: Change From Baseline in Mean Volume of Full Field Hill of Vision
Change From Baseline at Month 6: Study Eye
|
—
|
—
|
-0.86 dBs
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
—
|
—
|
|
Part 1: Change From Baseline in Mean Volume of Full Field Hill of Vision
Change From Baseline at Month 6: Non-Study Eye
|
—
|
—
|
-4.91 dBs
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
—
|
—
|
|
Part 1: Change From Baseline in Mean Volume of Full Field Hill of Vision
Change From Baseline at Month 12: Non-Study Eye
|
—
|
—
|
-3.70 dBs
Standard Deviation NA
SD cannot be estimated for 1 participant.
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline, Months 3, 6, 12, and 24Population: Safety analysis set included all participants who received study treatment (vitrectomy/BIIB112). 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Change in CS was assessed by Pelli-Robson chart which uses a single large letter size (20/60 optotype), with contrast varying across groups of letters. Chart uses letters (6 per line), arranged in groups whose contrast varies from high to low. Participants read the letters, starting with the highest contrast, until they were unable to read two or three letters in a single group. Each group had three letters of the same contrast level, so there were three trials per contrast level. Participant is assigned a score based on the contrast of the last group in which two or three letters were correctly read. Score is a measure of the participant's log contrast sensitivity ranging from 0-2.25, with 0 being no letters read, and 2.25 being all letters read. Total CS score = \[(total letters correct - 3) x 0.05\].
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=6 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 1: Change From Baseline in Contrast Sensitivity (CS) Score
Baseline: Study Eye
|
0.883 Score on scale
Standard Deviation 0.3884
|
1.267 Score on scale
Standard Deviation 0.0289
|
1.067 Score on scale
Standard Deviation 0.6110
|
0.300 Score on scale
Standard Deviation 0.1732
|
0.533 Score on scale
Standard Deviation 0.2309
|
0.900 Score on scale
Standard Deviation 0.1732
|
|
Part 1: Change From Baseline in Contrast Sensitivity (CS) Score
Baseline: Non-Study
|
0.933 Score on scale
Standard Deviation 0.4646
|
1.350 Score on scale
Standard Deviation 0.1803
|
1.100 Score on scale
Standard Deviation 0.3279
|
0.433 Score on scale
Standard Deviation 0.2082
|
0.583 Score on scale
Standard Deviation 0.2255
|
1.050 Score on scale
Standard Deviation 0.2598
|
|
Part 1: Change From Baseline in Contrast Sensitivity (CS) Score
Change From Baseline at Month 3: Study Eye
|
0.133 Score on scale
Standard Deviation 0.1155
|
-0.033 Score on scale
Standard Deviation 0.4163
|
-0.167 Score on scale
Standard Deviation 0.3014
|
0.167 Score on scale
Standard Deviation 0.1528
|
0.183 Score on scale
Standard Deviation 0.2566
|
0.150 Score on scale
Standard Deviation 0.0866
|
|
Part 1: Change From Baseline in Contrast Sensitivity (CS) Score
Change From Baseline at Month 3: Non-Study Eye
|
0.050 Score on scale
Standard Deviation 0.0500
|
0.100 Score on scale
Standard Deviation 0.0000
|
0.000 Score on scale
Standard Deviation 0.1000
|
0.000 Score on scale
Standard Deviation 0.0000
|
0.017 Score on scale
Standard Deviation 0.4010
|
0.050 Score on scale
Standard Deviation 0.0500
|
|
Part 1: Change From Baseline in Contrast Sensitivity (CS) Score
Change From Baseline at Month 6: Non-Study Eye
|
0.050 Score on scale
Standard Deviation 0.1000
|
-0.100 Score on scale
Standard Deviation 0.0500
|
0.000 Score on scale
Standard Deviation 0.0500
|
0.000 Score on scale
Standard Deviation 0.1732
|
0.033 Score on scale
Standard Deviation 0.2255
|
0.083 Score on scale
Standard Deviation 0.0764
|
|
Part 1: Change From Baseline in Contrast Sensitivity (CS) Score
Change From Baseline at Month 12: Study Eye
|
0.183 Score on scale
Standard Deviation 0.0577
|
-0.167 Score on scale
Standard Deviation 0.6788
|
-0.017 Score on scale
Standard Deviation 0.3329
|
0.100 Score on scale
Standard Deviation 0.2828
|
0.133 Score on scale
Standard Deviation 0.3512
|
-0.017 Score on scale
Standard Deviation 0.1041
|
|
Part 1: Change From Baseline in Contrast Sensitivity (CS) Score
Change From Baseline at Month 24: Non-Study Eye
|
0.017 Score on scale
Standard Deviation 0.2021
|
-0.050 Score on scale
Standard Deviation 0.1323
|
0.050 Score on scale
Standard Deviation 0.0500
|
-0.183 Score on scale
Standard Deviation 0.1258
|
0.117 Score on scale
Standard Deviation 0.3884
|
-0.100 Score on scale
Standard Deviation 0.1732
|
|
Part 1: Change From Baseline in Contrast Sensitivity (CS) Score
Change From Baseline at Month 6: Study Eye
|
0.133 Score on scale
Standard Deviation 0.0577
|
-0.183 Score on scale
Standard Deviation 0.4072
|
0.117 Score on scale
Standard Deviation 0.2021
|
0.133 Score on scale
Standard Deviation 0.2082
|
0.067 Score on scale
Standard Deviation 0.2363
|
0.100 Score on scale
Standard Deviation 0.1323
|
|
Part 1: Change From Baseline in Contrast Sensitivity (CS) Score
Change From Baseline at Month 12: Non-Study Eye
|
0.000 Score on scale
Standard Deviation 0.0500
|
-0.100 Score on scale
Standard Deviation 0.1323
|
-0.050 Score on scale
Standard Deviation 0.1323
|
-0.100 Score on scale
Standard Deviation 0.2828
|
0.067 Score on scale
Standard Deviation 0.3512
|
0.000 Score on scale
Standard Deviation 0.0000
|
|
Part 1: Change From Baseline in Contrast Sensitivity (CS) Score
Change From Baseline at Month 24: Study Eye
|
0.217 Score on scale
Standard Deviation 0.1893
|
-0.217 Score on scale
Standard Deviation 0.5346
|
-0.117 Score on scale
Standard Deviation 0.2466
|
0.000 Score on scale
Standard Deviation 0.2291
|
0.017 Score on scale
Standard Deviation 0.5965
|
-0.100 Score on scale
Standard Deviation 0.0000
|
SECONDARY outcome
Timeframe: Months 1, 2, 3, 6, and 9Population: ITT analysis set included all participants who were randomized, under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
MAIA microperimetry assessment was measured in dBs using a 10-2 grid of 68 points. Each point was labelled as '\< 0', '0' or a positive integer. The point labelled as '\< 0' is assigned a value of '-1' by MAIA in the calculation. Improvement in mean sensitivity in center grid was defined as an increase from baseline of 7 or more dBs in any 5 or more points out of the 16 central points.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=9 study eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=10 study eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=10 study eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 2: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Month 1
|
—
|
—
|
—
|
22.2 percentage of study eyes
Interval 6.1 to 49.0
|
30.0 percentage of study eyes
Interval 11.6 to 55.2
|
40.0 percentage of study eyes
Interval 18.8 to 64.6
|
|
Part 2: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Month 2
|
—
|
—
|
—
|
22.2 percentage of study eyes
Interval 6.1 to 49.0
|
30.0 percentage of study eyes
Interval 11.6 to 55.2
|
50.0 percentage of study eyes
Interval 26.7 to 73.3
|
|
Part 2: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Month 3
|
—
|
—
|
—
|
12.5 percentage of study eyes
Interval 1.3 to 40.6
|
30.0 percentage of study eyes
Interval 11.6 to 55.2
|
60.0 percentage of study eyes
Interval 35.4 to 81.2
|
|
Part 2: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Month 6
|
—
|
—
|
—
|
22.2 percentage of study eyes
Interval 6.1 to 49.0
|
33.3 percentage of study eyes
Interval 12.9 to 59.9
|
62.5 percentage of study eyes
Interval 34.5 to 85.3
|
|
Part 2: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Month 9
|
—
|
—
|
—
|
22.2 percentage of study eyes
Interval 6.1 to 49.0
|
28.6 percentage of study eyes
Interval 7.9 to 59.6
|
42.9 percentage of study eyes
Interval 17.0 to 72.1
|
SECONDARY outcome
Timeframe: Months 1, 2, 3, 6, 9, and 12Population: ITT analysis set included all participants who were randomized, under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
MAIA microperimetry assessment was measured in dBs using a 10-2 grid of 68 points. Each point was labelled as '\< 0', '0' or a positive integer. The point labelled as '\< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in mean sensitivity in whole grid was defined as an increase from baseline of 7 or more dBs in any 5 or more points of the grid as a whole (68 points).
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=9 study eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=10 study eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=10 study eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 2: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 68 Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Month 9
|
—
|
—
|
—
|
33.3 percentage of study eyes
Interval 12.9 to 59.9
|
85.7 percentage of study eyes
Interval 54.7 to 98.5
|
71.4 percentage of study eyes
Interval 40.4 to 92.1
|
|
Part 2: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 68 Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Month 1
|
—
|
—
|
—
|
33.3 percentage of study eyes
Interval 12.9 to 59.9
|
60.0 percentage of study eyes
Interval 35.4 to 81.2
|
40.0 percentage of study eyes
Interval 18.8 to 64.6
|
|
Part 2: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 68 Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Month 2
|
—
|
—
|
—
|
22.2 percentage of study eyes
Interval 6.1 to 49.0
|
80.0 percentage of study eyes
Interval 55.0 to 94.5
|
80.0 percentage of study eyes
Interval 55.0 to 94.5
|
|
Part 2: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 68 Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Month 3
|
—
|
—
|
—
|
25.0 percentage of study eyes
Interval 6.9 to 53.8
|
80.0 percentage of study eyes
Interval 55.0 to 94.5
|
70.0 percentage of study eyes
Interval 44.8 to 88.4
|
|
Part 2: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 68 Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Month 6
|
—
|
—
|
—
|
33.3 percentage of study eyes
Interval 12.9 to 59.9
|
77.8 percentage of study eyes
Interval 51.0 to 93.9
|
100.0 percentage of study eyes
Interval 75.0 to 100.0
|
|
Part 2: Percentage of Study Eyes With ≥7 dB Improvement From Baseline at ≥5 Points Out of the 68 Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Month 12
|
—
|
—
|
—
|
33.3 percentage of study eyes
Interval 12.9 to 59.9
|
62.5 percentage of study eyes
Interval 34.5 to 85.3
|
62.5 percentage of study eyes
Interval 34.5 to 85.3
|
SECONDARY outcome
Timeframe: Baseline, Months 1, 2, 3, 6, 9, and 12Population: ITT analysis set included all participants who were randomized, under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '\< 0', '0' or a positive integer. The point labelled as '\< 0' was assigned a value of '-1' by MAIA in the calculation. Mean Sensitivity in center grid was defined as the mean in dB of the 16 points located in the center of the grid. Here negative values indicate a decline in retinal sensitivity.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=18 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 2: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Change From Baseline at Month 2: Study Eye
|
—
|
—
|
—
|
1.62 dBs
Standard Deviation 2.846
|
2.73 dBs
Standard Deviation 4.360
|
1.55 dBs
Standard Deviation 5.886
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Change From Baseline at Month 2: Non-Study Eye
|
—
|
—
|
—
|
-0.34 dBs
Standard Deviation 2.027
|
-0.44 dBs
Standard Deviation 1.723
|
0.26 dBs
Standard Deviation 1.118
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Change From Baseline at Month 6: Non-Study Eye
|
—
|
—
|
—
|
-0.69 dBs
Standard Deviation 2.199
|
-0.35 dBs
Standard Deviation 1.125
|
-0.66 dBs
Standard Deviation 0.702
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Baseline: Study Eye
|
—
|
—
|
—
|
6.78 dBs
Standard Deviation 3.488
|
7.39 dBs
Standard Deviation 5.207
|
7.38 dBs
Standard Deviation 3.095
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Baseline: Non-Study Eye
|
—
|
—
|
—
|
9.56 dBs
Standard Deviation 3.321
|
9.09 dBs
Standard Deviation 5.003
|
8.98 dBs
Standard Deviation 3.583
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Change From Baseline at Month 1: Study Eye
|
—
|
—
|
—
|
1.53 dBs
Standard Deviation 3.086
|
2.70 dBs
Standard Deviation 3.731
|
0.10 dBs
Standard Deviation 5.723
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Change From Baseline at Month 1: Non-Study Eye
|
—
|
—
|
—
|
-0.26 dBs
Standard Deviation 1.692
|
-0.76 dBs
Standard Deviation 1.793
|
-0.08 dBs
Standard Deviation 0.834
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Change From Baseline at Month 3: Study Eye
|
—
|
—
|
—
|
1.17 dBs
Standard Deviation 2.760
|
2.77 dBs
Standard Deviation 4.598
|
1.00 dBs
Standard Deviation 6.862
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Change From Baseline at Month 3: Non-Study Eye
|
—
|
—
|
—
|
-1.24 dBs
Standard Deviation 1.253
|
0.07 dBs
Standard Deviation 1.393
|
-0.24 dBs
Standard Deviation 0.500
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Change From Baseline at Month 6: Study Eye
|
—
|
—
|
—
|
0.72 dBs
Standard Deviation 3.208
|
3.38 dBs
Standard Deviation 4.770
|
3.74 dBs
Standard Deviation 3.931
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Change From Baseline at Month 9: Study Eye
|
—
|
—
|
—
|
0.65 dBs
Standard Deviation 3.272
|
2.52 dBs
Standard Deviation 4.619
|
2.54 dBs
Standard Deviation 6.317
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Change From Baseline at Month 9: Non-Study Eye
|
—
|
—
|
—
|
-1.01 dBs
Standard Deviation 1.943
|
0.30 dBs
Standard Deviation 1.654
|
-0.54 dBs
Standard Deviation 0.636
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Change From Baseline at Month 12: Study Eye
|
—
|
—
|
—
|
-0.11 dBs
Standard Deviation 4.446
|
2.79 dBs
Standard Deviation 4.663
|
1.16 dBs
Standard Deviation 5.660
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 16 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Change From Baseline at Month 12: Non-Study Eye
|
—
|
—
|
—
|
-2.23 dBs
Standard Deviation 4.018
|
-0.44 dBs
Standard Deviation 1.078
|
-1.04 dBs
Standard Deviation 1.292
|
SECONDARY outcome
Timeframe: Baseline, Months 1, 2, 3, 6, 9, and 12Population: ITT analysis set included all participants who were randomized, under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labelled as '\< 0', '0' or a positive integer. The point labelled as '\< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in mean ensitivity in whole grid was defined as an increase from baseline of 7 or more dBs in any 5 or more points of the grid as a whole (68 points). Here negative values indicate a decline in retinal sensitivity.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=18 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 2: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Baseline: Study Eye
|
—
|
—
|
—
|
2.15 dBs
Standard Deviation 2.182
|
2.46 dBs
Standard Deviation 1.911
|
3.84 dBs
Standard Deviation 2.138
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Change From Baseline at Month 9: Non- Study Eye
|
—
|
—
|
—
|
-0.41 dBs
Standard Deviation 1.150
|
-0.05 dBs
Standard Deviation 0.790
|
0.09 dBs
Standard Deviation 0.544
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Change From Baseline at Month 12: Study Eye
|
—
|
—
|
—
|
0.11 dBs
Standard Deviation 1.592
|
2.79 dBs
Standard Deviation 3.045
|
0.89 dBs
Standard Deviation 3.132
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Baseline: Non-Study Eye
|
—
|
—
|
—
|
3.32 dBs
Standard Deviation 2.539
|
3.34 dBs
Standard Deviation 2.092
|
4.47 dBs
Standard Deviation 2.331
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Change From Baseline at Month 1: Study Eye
|
—
|
—
|
—
|
0.91 dBs
Standard Deviation 1.389
|
1.60 dBs
Standard Deviation 2.225
|
-0.07 dBs
Standard Deviation 3.898
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Change From Baseline at Month 1: Non-Study Eye
|
—
|
—
|
—
|
0.12 dBs
Standard Deviation 1.214
|
-0.46 dBs
Standard Deviation 1.044
|
-0.03 dBs
Standard Deviation 0.850
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Change From Baseline at Month 2: Study Eye
|
—
|
—
|
—
|
0.90 dBs
Standard Deviation 0.972
|
2.34 dBs
Standard Deviation 2.353
|
1.18 dBs
Standard Deviation 3.367
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Change From Baseline at Month 2: Non-Study Eye
|
—
|
—
|
—
|
0.30 dBs
Standard Deviation 1.111
|
-0.23 dBs
Standard Deviation 0.859
|
0.13 dBs
Standard Deviation 0.668
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Change From Baseline at Month 3: Study Eye
|
—
|
—
|
—
|
0.46 dBs
Standard Deviation 1.064
|
2.64 dBs
Standard Deviation 2.962
|
0.24 dBs
Standard Deviation 3.962
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Change From Baseline at Month 3: Non-Study Eye
|
—
|
—
|
—
|
-0.16 dBs
Standard Deviation 0.743
|
-0.03 dBs
Standard Deviation 0.516
|
-0.11 dBs
Standard Deviation 0.619
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Change From Baseline at Month 6: Study Eye
|
—
|
—
|
—
|
0.32 dBs
Standard Deviation 1.301
|
3.15 dBs
Standard Deviation 3.283
|
2.05 dBs
Standard Deviation 3.007
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Change From Baseline at Month 6: Non-Study Eye
|
—
|
—
|
—
|
-0.13 dBs
Standard Deviation 1.283
|
-0.27 dBs
Standard Deviation 0.527
|
-0.50 dBs
Standard Deviation 0.632
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Change From Baseline at Month 9: Study Eye
|
—
|
—
|
—
|
0.40 dBs
Standard Deviation 1.456
|
2.80 dBs
Standard Deviation 3.116
|
1.71 dBs
Standard Deviation 3.605
|
|
Part 2: Change From Baseline in Mean Sensitivity of the 68 Central Loci Points of the 10-2 Grid Assessed by MAIA Microperimetry
Change From Baseline at Month 12: Non-Study Eye
|
—
|
—
|
—
|
-0.84 dBs
Standard Deviation 1.749
|
-0.28 dBs
Standard Deviation 0.476
|
-0.35 dBs
Standard Deviation 1.004
|
SECONDARY outcome
Timeframe: Baseline, Months 1, 2, 3, 6, 9, and 12Population: ITT analysis set included all participants who were randomized, under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was reported as number of letters read correctly by the participant, using the ETDRS Scale (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). An increase in the number of letters read correctly means that vision has improved. Here negative values indicate a decline in BCVA.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=18 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 2: Change From Baseline in BCVA Reported as Letters
Change From Baseline at Month 6: Study Eye
|
—
|
—
|
—
|
1.00 letters
Standard Deviation 2.000
|
2.44 letters
Standard Deviation 5.003
|
-0.38 letters
Standard Deviation 5.630
|
|
Part 2: Change From Baseline in BCVA Reported as Letters
Change From Baseline at Month 9: Non-Study Eye
|
—
|
—
|
—
|
-1.78 letters
Standard Deviation 2.949
|
1.00 letters
Standard Deviation 2.000
|
1.71 letters
Standard Deviation 3.147
|
|
Part 2: Change From Baseline in BCVA Reported as Letters
Change From Baseline at Month 12: Study Eye
|
—
|
—
|
—
|
0.22 letters
Standard Deviation 2.949
|
-4.00 letters
Standard Deviation 17.436
|
-0.75 letters
Standard Deviation 3.370
|
|
Part 2: Change From Baseline in BCVA Reported as Letters
Change From Baseline at Month 12: Non-Study Eye
|
—
|
—
|
—
|
-4.11 letters
Standard Deviation 3.983
|
0.89 letters
Standard Deviation 3.100
|
2.14 letters
Standard Deviation 3.976
|
|
Part 2: Change From Baseline in BCVA Reported as Letters
Baseline: Study Eye
|
—
|
—
|
—
|
68.78 letters
Standard Deviation 5.954
|
65.90 letters
Standard Deviation 10.104
|
68.20 letters
Standard Deviation 8.991
|
|
Part 2: Change From Baseline in BCVA Reported as Letters
Baseline: Non-Study Eye
|
—
|
—
|
—
|
72.89 letters
Standard Deviation 6.846
|
68.50 letters
Standard Deviation 9.675
|
68.80 letters
Standard Deviation 6.989
|
|
Part 2: Change From Baseline in BCVA Reported as Letters
Change From Baseline at Month 1: Study Eye
|
—
|
—
|
—
|
0.44 letters
Standard Deviation 2.833
|
1.60 letters
Standard Deviation 6.450
|
0.60 letters
Standard Deviation 7.545
|
|
Part 2: Change From Baseline in BCVA Reported as Letters
Change From Baseline at Month 1: Non-Study Eye
|
—
|
—
|
—
|
-0.89 letters
Standard Deviation 2.028
|
0.00 letters
Standard Deviation 4.110
|
3.80 letters
Standard Deviation 3.360
|
|
Part 2: Change From Baseline in BCVA Reported as Letters
Change From Baseline at Month 2: Study Eye
|
—
|
—
|
—
|
0.22 letters
Standard Deviation 2.108
|
-1.00 letters
Standard Deviation 12.392
|
0.00 letters
Standard Deviation 8.957
|
|
Part 2: Change From Baseline in BCVA Reported as Letters
Change From Baseline at Month 2: Non-Study Eye
|
—
|
—
|
—
|
-0.11 letters
Standard Deviation 1.269
|
0.60 letters
Standard Deviation 2.836
|
3.10 letters
Standard Deviation 2.644
|
|
Part 2: Change From Baseline in BCVA Reported as Letters
Change From Baseline at Month 3: Study Eye
|
—
|
—
|
—
|
1.38 letters
Standard Deviation 2.615
|
0.10 letters
Standard Deviation 6.540
|
-0.30 letters
Standard Deviation 11.036
|
|
Part 2: Change From Baseline in BCVA Reported as Letters
Change From Baseline at Month 3: Non-Study Eye
|
—
|
—
|
—
|
0.13 letters
Standard Deviation 2.642
|
1.10 letters
Standard Deviation 2.470
|
3.20 letters
Standard Deviation 2.860
|
|
Part 2: Change From Baseline in BCVA Reported as Letters
Change From Baseline at Month 6: Non-Study Eye
|
—
|
—
|
—
|
-1.56 letters
Standard Deviation 2.833
|
0.67 letters
Standard Deviation 1.581
|
1.00 letters
Standard Deviation 4.629
|
|
Part 2: Change From Baseline in BCVA Reported as Letters
Change From Baseline at Month 9: Study Eye
|
—
|
—
|
—
|
0.44 letters
Standard Deviation 1.944
|
-2.50 letters
Standard Deviation 14.263
|
-0.57 letters
Standard Deviation 1.397
|
SECONDARY outcome
Timeframe: Baseline, Months 1, 3, 6, 9, and 12Population: ITT analysis set included all participants who were randomized, under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the participant, using the ETDRS Scale (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). An increase in the number of letters read correctly means that vision has improved. Here negative values indicate a decline in LLVA.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=18 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 2: Change From Baseline in Mean LLVA Reported as Letters
Change From Baseline at Month 6: Non-Study Eye
|
—
|
—
|
—
|
0.11 letters
Standard Deviation 6.274
|
-3.56 letters
Standard Deviation 8.472
|
2.13 letters
Standard Deviation 2.850
|
|
Part 2: Change From Baseline in Mean LLVA Reported as Letters
Change From Baseline at Month 12: Non-Study Eye
|
—
|
—
|
—
|
-4.44 letters
Standard Deviation 7.002
|
-3.56 letters
Standard Deviation 11.652
|
-1.50 letters
Standard Deviation 4.309
|
|
Part 2: Change From Baseline in Mean LLVA Reported as Letters
Baseline: Study Eye
|
—
|
—
|
—
|
50.22 letters
Standard Deviation 13.349
|
39.30 letters
Standard Deviation 22.246
|
47.90 letters
Standard Deviation 14.970
|
|
Part 2: Change From Baseline in Mean LLVA Reported as Letters
Baseline: Non-Study Eye
|
—
|
—
|
—
|
54.78 letters
Standard Deviation 11.872
|
49.50 letters
Standard Deviation 19.127
|
51.60 letters
Standard Deviation 9.524
|
|
Part 2: Change From Baseline in Mean LLVA Reported as Letters
Change From Baseline at Month 1: Study Eye
|
—
|
—
|
—
|
0.56 letters
Standard Deviation 7.618
|
11.30 letters
Standard Deviation 16.918
|
-1.30 letters
Standard Deviation 18.397
|
|
Part 2: Change From Baseline in Mean LLVA Reported as Letters
Change From Baseline at Month 1: Non-Study Eye
|
—
|
—
|
—
|
0.22 letters
Standard Deviation 5.215
|
-3.00 letters
Standard Deviation 9.165
|
3.50 letters
Standard Deviation 4.882
|
|
Part 2: Change From Baseline in Mean LLVA Reported as Letters
Change From Baseline at Month 3: Study Eye
|
—
|
—
|
—
|
3.63 letters
Standard Deviation 7.230
|
8.10 letters
Standard Deviation 16.251
|
-3.50 letters
Standard Deviation 22.609
|
|
Part 2: Change From Baseline in Mean LLVA Reported as Letters
Change From Baseline at Month 3: Non-Study Eye
|
—
|
—
|
—
|
-0.63 letters
Standard Deviation 8.158
|
0.50 letters
Standard Deviation 3.749
|
1.20 letters
Standard Deviation 3.553
|
|
Part 2: Change From Baseline in Mean LLVA Reported as Letters
Change From Baseline at Month 6: Study Eye
|
—
|
—
|
—
|
1.22 letters
Standard Deviation 7.032
|
8.00 letters
Standard Deviation 18.581
|
3.25 letters
Standard Deviation 14.636
|
|
Part 2: Change From Baseline in Mean LLVA Reported as Letters
Change From Baseline at Month 9: Study Eye
|
—
|
—
|
—
|
-1.78 letters
Standard Deviation 7.225
|
8.38 letters
Standard Deviation 16.088
|
6.00 letters
Standard Deviation 12.356
|
|
Part 2: Change From Baseline in Mean LLVA Reported as Letters
Change From Baseline at Month 9: Non-Study Eye
|
—
|
—
|
—
|
-3.11 letters
Standard Deviation 7.491
|
-1.13 letters
Standard Deviation 6.749
|
4.00 letters
Standard Deviation 4.082
|
|
Part 2: Change From Baseline in Mean LLVA Reported as Letters
Change From Baseline at Month 12: Study Eye
|
—
|
—
|
—
|
-2.22 letters
Standard Deviation 7.412
|
5.11 letters
Standard Deviation 14.426
|
-0.63 letters
Standard Deviation 11.575
|
SECONDARY outcome
Timeframe: Months 1, 2, 3, 6, 9, and 12Population: ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥15 letters increase from baseline for BCVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=18 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for BCVA
Month 12: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
|
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for BCVA
Month 1: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
10.0 percentage of eyes
Interval 1.0 to 33.7
|
|
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for BCVA
Month 1: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
|
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for BCVA
Month 2: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
10.0 percentage of eyes
Interval 1.0 to 33.7
|
|
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for BCVA
Month 2: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
|
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for BCVA
Month 3: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
10.0 percentage of eyes
Interval 1.0 to 33.7
|
|
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for BCVA
Month 3: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
|
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for BCVA
Month 6: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
|
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for BCVA
Month 6: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
|
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for BCVA
Month 9: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
0.0 percentage of eyes
Interval 0.0 to 28.0
|
|
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for BCVA
Month 9: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
0.0 percentage of eyes
Interval 0.0 to 28.0
|
|
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for BCVA
Month 12: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 28.0
|
SECONDARY outcome
Timeframe: Months 1, 3, 6, 9, and 12Population: ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. "Number analyzed" signifies the number of participants with data available for analysis at specified timepoint.
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥15 letters increase from baseline for LLVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=18 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for LLVA
Month 1: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
40.0 percentage of eyes
Interval 18.8 to 64.6
|
20.0 percentage of eyes
Interval 5.5 to 45.0
|
|
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for LLVA
Month 1: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
10.0 percentage of eyes
Interval 1.0 to 33.7
|
|
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for LLVA
Month 3: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
40.0 percentage of eyes
Interval 18.8 to 64.6
|
30.0 percentage of eyes
Interval 11.6 to 55.2
|
|
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for LLVA
Month 3: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
|
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for LLVA
Month 6: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
33.3 percentage of eyes
Interval 12.9 to 59.9
|
12.5 percentage of eyes
Interval 1.3 to 40.6
|
|
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for LLVA
Month 9: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
0.0 percentage of eyes
Interval 0.0 to 28.0
|
|
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for LLVA
Month 12: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
33.3 percentage of eyes
Interval 12.9 to 59.9
|
12.5 percentage of eyes
Interval 1.3 to 40.6
|
|
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for LLVA
Month 6: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 0.0
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
|
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for LLVA
Month 9: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
25.0 percentage of eyes
Interval 6.9 to 53.8
|
28.6 percentage of eyes
Interval 7.9 to 59.6
|
|
Part 2: Percentage of Eyes With a ≥15 Letter Increase From Baseline for LLVA
Month 12: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
SECONDARY outcome
Timeframe: Months 1, 2, 3, 6, 9, and 12Population: ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). An increase in the number of letters read correctly means that vision has improved. Percentage of eyes with a ≥10 letters increase from baseline for BCVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=18 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for BCVA
Month 1: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
10.0 percentage of eyes
Interval 1.0 to 33.7
|
|
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for BCVA
Month 2: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
|
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for BCVA
Month 3: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
10.0 percentage of eyes
Interval 1.0 to 33.7
|
|
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for BCVA
Month 12: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 28.0
|
|
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for BCVA
Month 1: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
10.0 percentage of eyes
Interval 1.0 to 33.7
|
|
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for BCVA
Month 2: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
20.0 percentage of eyes
Interval 5.5 to 45.0
|
|
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for BCVA
Month 3: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
|
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for BCVA
Month 6: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
12.5 percentage of eyes
Interval 1.3 to 40.6
|
|
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for BCVA
Month 6: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
|
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for BCVA
Month 9: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 28.0
|
|
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for BCVA
Month 9: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
0.0 percentage of eyes
Interval 0.0 to 28.0
|
|
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for BCVA
Month 12: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
SECONDARY outcome
Timeframe: Months 1, 3, 6, 9, and 12Population: ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥10 letters increase from baseline for LLVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=9 Participants
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for LLVA
Month 3: Study Eye
|
—
|
—
|
—
|
25.0 percentage of eyes
Interval 6.9 to 53.8
|
40.0 percentage of eyes
Interval 18.8 to 64.6
|
30.0 percentage of eyes
Interval 11.6 to 55.2
|
|
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for LLVA
Month 3: Non-Study Eye
|
—
|
—
|
—
|
12.5 percentage of eyes
Interval 1.3 to 40.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
|
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for LLVA
Month 6: Non-Study Eye
|
—
|
—
|
—
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
|
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for LLVA
Month 9: Non-Study Eye
|
—
|
—
|
—
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
12.5 percentage of eyes
Interval 1.3 to 40.6
|
14.3 percentage of eyes
Interval 1.5 to 45.3
|
|
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for LLVA
Month 12: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
|
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for LLVA
Month 1: Study Eye
|
—
|
—
|
—
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
40.0 percentage of eyes
Interval 18.8 to 64.6
|
30.0 percentage of eyes
Interval 11.6 to 55.2
|
|
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for LLVA
Month 1: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
|
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for LLVA
Month 6: Study Eye
|
—
|
—
|
—
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
44.4 percentage of eyes
Interval 21.0 to 69.9
|
14.7 percentage of eyes
Interval 14.7 to 65.5
|
|
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for LLVA
Month 9: Study Eye
|
—
|
—
|
—
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
37.5 percentage of eyes
Interval 14.7 to 65.5
|
28.6 percentage of eyes
Interval 7.9 to 59.6
|
|
Part 2: Percentage of Eyes With a ≥10 Letter Increase From Baseline for LLVA
Month 12: Study Eye
|
—
|
—
|
—
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
33.3 percentage of eyes
Interval 12.9 to 59.9
|
12.5 percentage of eyes
Interval 1.3 to 40.6
|
SECONDARY outcome
Timeframe: Months 1, 2, 3, 6, 9, and 12Population: ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters increase from baseline for BCVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=18 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for BCVA
Month 2: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
30.0 percentage of eyes
Interval 11.6 to 55.2
|
|
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for BCVA
Month 3: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
20.0 percentage of eyes
Interval 5.5 to 45.0
|
|
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for BCVA
Month 9: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
37.5 percentage of eyes
Interval 14.7 to 65.5
|
0.0 percentage of eyes
Interval 0.0 to 28.0
|
|
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for BCVA
Month 9: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
42.9 percentage of eyes
Interval 17.0 to 72.1
|
|
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for BCVA
Month 1: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
60.0 percentage of eyes
Interval 35.4 to 81.2
|
20.0 percentage of eyes
Interval 5.5 to 45.0
|
|
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for BCVA
Month 1: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
10.0 percentage of eyes
Interval 1.0 to 33.7
|
40.0 percentage of eyes
Interval 18.8 to 64.6
|
|
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for BCVA
Month 2: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
60.0 percentage of eyes
Interval 35.4 to 81.2
|
30.0 percentage of eyes
Interval 11.6 to 55.2
|
|
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for BCVA
Month 3: Study Eye
|
—
|
—
|
—
|
12.5 percentage of eyes
Interval 1.3 to 40.6
|
20.0 percentage of eyes
Interval 5.5 to 45.0
|
30.0 percentage of eyes
Interval 11.6 to 55.2
|
|
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for BCVA
Month 6: Study Eye
|
—
|
—
|
—
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
44.4 percentage of eyes
Interval 21.0 to 69.9
|
12.5 percentage of eyes
Interval 1.3 to 40.6
|
|
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for BCVA
Month 6: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
25.0 percentage of eyes
Interval 6.9 to 53.8
|
|
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for BCVA
Month 12: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
22.2 percentage of eyes
Interval 6.1 to 49.0
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
|
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for BCVA
Month 12: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
28.6 percentage of eyes
Interval 7.9 to 59.6
|
SECONDARY outcome
Timeframe: Months 1, 3, 6, 9, and 12Population: ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters increase from baseline for LLVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=18 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for LLVA
Month 1: Non-Study Eye
|
—
|
—
|
—
|
22.2 percentage of eyes
Interval 6.1 to 49.0
|
30.0 percentage of eyes
Interval 11.6 to 55.2
|
30.0 percentage of eyes
Interval 11.6 to 55.2
|
|
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for LLVA
Month 3: Study Eye
|
—
|
—
|
—
|
37.5 percentage of eyes
Interval 14.7 to 65.5
|
50.0 percentage of eyes
Interval 26.7 to 73.3
|
30.0 percentage of eyes
Interval 11.6 to 55.2
|
|
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for LLVA
Month 6: Study Eye
|
—
|
—
|
—
|
44.4 percentage of eyes
Interval 21.0 to 69.9
|
66.7 percentage of eyes
Interval 40.1 to 87.1
|
50.0 percentage of eyes
Interval 24.0 to 76.0
|
|
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for LLVA
Month 1: Study Eye
|
—
|
—
|
—
|
22.2 percentage of eyes
Interval 6.1 to 49.0
|
60.0 percentage of eyes
Interval 35.4 to 81.2
|
40.0 percentage of eyes
Interval 18.8 to 64.6
|
|
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for LLVA
Month 3: Non-Study Eye
|
—
|
—
|
—
|
25.0 percentage of eyes
Interval 25.0 to 53.8
|
20.0 percentage of eyes
Interval 5.5 to 45.0
|
10.0 percentage of eyes
Interval 1.0 to 33.7
|
|
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for LLVA
Month 6: Non-Study Eye
|
—
|
—
|
—
|
22.2 percentage of eyes
Interval 6.1 to 49.0
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
25.0 percentage of eyes
Interval 6.9 to 53.8
|
|
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for LLVA
Month 9: Study Eye
|
—
|
—
|
—
|
22.2 percentage of eyes
Interval 6.1 to 49.0
|
62.5 percentage of eyes
Interval 34.5 to 85.3
|
57.1 percentage of eyes
Interval 27.9 to 83.0
|
|
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for LLVA
Month 9: Non-Study Eye
|
—
|
—
|
—
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
12.5 percentage of eyes
Interval 1.3 to 40.6
|
42.9 percentage of eyes
Interval 17.0 to 72.1
|
|
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for LLVA
Month 12: Study Eye
|
—
|
—
|
—
|
22.2 percentage of eyes
Interval 6.1 to 49.0
|
44.4 percentage of eyes
Interval 21.0 to 69.9
|
12.5 percentage of eyes
Interval 1.3 to 40.6
|
|
Part 2: Percentage of Eyes With a ≥5 Letter Increase From Baseline for LLVA
Month 12: Non-Study Eye
|
—
|
—
|
—
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
22.2 percentage of eyes
Interval 6.1 to 49.0
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
SECONDARY outcome
Timeframe: Months 1, 2, 3, 6, 9, and 12Population: ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters loss from baseline for BCVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=18 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 2: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
10.0 percentage of eyes
Interval 1.0 to 33.7
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
|
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 3: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
0.0 percentage of eyes
Interval 0.0 to 18.9
|
8.3 percentage of eyes
Interval 0.9 to 28.7
|
|
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 3: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
0.0 percentage of eyes
Interval 0.0 to 18.9
|
0.0 percentage of eyes
Interval 0.0 to 17.5
|
|
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 6: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
|
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 9: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
|
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 1: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 18.9
|
8.3 percentage of eyes
Interval 0.9 to 28.7
|
|
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 1: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 18.9
|
0.0 percentage of eyes
Interval 0.0 to 17.5
|
|
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 2: Non- Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
|
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 6: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
|
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 9: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
|
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 12: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
10.0 percentage of eyes
Interval 1.0 to 33.7
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
|
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for BCVA
Month 12: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 222.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
SECONDARY outcome
Timeframe: Months 1, 3, 6, 9, and 12Population: ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥15 letters loss from baseline for LLVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=18 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
Month 6: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
10.0 percentage of eyes
Interval 1.0 to 33.7
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
|
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
Month 3: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
0.0 percentage of eyes
Interval 0.0 to 18.9
|
0.0 percentage of eyes
Interval 0.0 to 17.5
|
|
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
Month 9: Non-Study Eye
|
—
|
—
|
—
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
|
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
Month 12: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
10.0 percentage of eyes
Interval 1.0 to 33.7
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
|
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
Month 1: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 18.9
|
33.3 percentage of eyes
Interval 15.4 to 55.9
|
|
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
Month 1: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
18.2 percentage of eyes
Interval 4.9 to 41.5
|
0.0 percentage of eyes
Interval 0.0 to 17.5
|
|
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
Month 3: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
9.1 percentage of eyes
Interval 1.0 to 31.0
|
33.3 percentage of eyes
Interval 15.4 to 55.9
|
|
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
Month 6: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
20.0 percentage of eyes
Interval 5.5 to 45.0
|
20.0 percentage of eyes
Interval 5.5 to 45.0
|
|
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
Month 9: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
|
Part 2: Percentage of Eyes With a ≥15 Letters Loss From Baseline for LLVA
Month 12: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
10.0 percentage of eyes
Interval 1.0 to 33.7
|
20.0 percentage of eyes
Interval 5.5 to 45.0
|
SECONDARY outcome
Timeframe: Months 1, 2, 3, 6, 9, and 12Population: ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥10 letters loss from baseline for BCVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=18 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 1: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
9.1 percentage of eyes
Interval 1.0 to 31.0
|
8.3 percentage of eyes
Interval 0.9 to 28.7
|
|
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 1: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 18.9
|
0.0 percentage of eyes
Interval 0.0 to 17.5
|
|
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 2: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
|
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 3: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
9.1 percentage of eyes
Interval 1.0 to 31.0
|
8.3 percentage of eyes
Interval 0.9 to 28.7
|
|
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 3: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
0.0 percentage of eyes
Interval 0.0 to 18.9
|
0.0 percentage of eyes
Interval 0.0 to 17.5
|
|
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 6: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
|
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 9: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
|
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 9: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
|
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 2: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
20.0 percentage of eyes
Interval 5.5 to 45.0
|
10.0 percentage of eyes
Interval 1.0 to 33.7
|
|
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 6: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
10.0 percentage of eyes
Interval 1.0 to 33.7
|
|
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 12: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
20.0 percentage of eyes
Interval 5.5 to 45.0
|
10.0 percentage of eyes
Interval 1.0 to 33.7
|
|
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for BCVA
Month 12: Non-Study Eye
|
—
|
—
|
—
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
SECONDARY outcome
Timeframe: Months 1, 3, 6, 9, and 12Population: ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥10 letters loss from baseline for LLVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=18 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
Month 1: Study Eye
|
—
|
—
|
—
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
0.0 percentage of eyes
Interval 0.0 to 18.9
|
33.3 percentage of eyes
Interval 15.4 to 55.9
|
|
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
Month 1: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
18.2 percentage of eyes
Interval 4.9 to 41.5
|
0.0 percentage of eyes
Interval 0.0 to 17.5
|
|
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
Month 6: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
20.0 percentage of eyes
Interval 5.5 to 45.0
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
|
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
Month 9: Non-Study Eye
|
—
|
—
|
—
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
0.0 percentage of eyes
Interval 0.0 to 0.0
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
|
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
Month 3: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
18.2 percentage of eyes
Interval 4.9 to 41.5
|
33.3 percentage of eyes
Interval 15.4 to 55.9
|
|
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
Month 3: Non-Study Eye
|
—
|
—
|
—
|
12.5 percentage of eyes
Interval 1.3 to 40.6
|
0.0 percentage of eyes
Interval 0.0 to 18.9
|
0.0 percentage of eyes
Interval 0.0 to 17.5
|
|
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
Month 6: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
20.0 percentage of eyes
Interval 5.5 to 45.0
|
20.0 percentage of eyes
Interval 5.5 to 45.0
|
|
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
Month 9: Study Eye
|
—
|
—
|
—
|
11.1 percentage of eyes
Interval 1.2 to 22.6
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
|
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
Month 12: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
10.0 percentage of eyes
Interval 1.0 to 33.7
|
30.0 percentage of eyes
Interval 11.6 to 55.2
|
|
Part 2: Percentage of Eyes With a ≥10 Letters Loss From Baseline for LLVA
Month 12: Non-Study Eye
|
—
|
—
|
—
|
33.3 percentage of eyes
Interval 12.9 to 59.9
|
10.0 percentage of eyes
Interval 1.0 to 33.7
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
SECONDARY outcome
Timeframe: Months 1, 2, 3, 6, 9, and 12Population: ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters loss from baseline for BCVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=18 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 2: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
20.0 percentage of eyes
Interval 5.5 to 45.0
|
40.0 percentage of eyes
Interval 18.8 to 64.6
|
|
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 6: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
10.0 percentage of eyes
Interval 1.0 to 33.7
|
30.0 percentage of eyes
Interval 11.6 to 55.2
|
|
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 6: Non-Study Eye
|
—
|
—
|
—
|
22.2 percentage of eyes
Interval 6.1 to 49.0
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
10.0 percentage of eyes
Interval 1.0 to 33.7
|
|
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 12: Study Eye
|
—
|
—
|
—
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
20.0 percentage of eyes
Interval 5.5 to 22.6
|
20.0 percentage of eyes
Interval 5.5 to 45.0
|
|
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 12: Non-Study Eye
|
—
|
—
|
—
|
33.3 percentage of eyes
Interval 12.9 to 59.9
|
10.0 percentage of eyes
Interval 1.0 to 33.7
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
|
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 1: Study Eye
|
—
|
—
|
—
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
9.1 percentage of eyes
Interval 1.0 to 31.0
|
33.3 percentage of eyes
Interval 15.4 to 55.9
|
|
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 1: Non-Study Eye
|
—
|
—
|
—
|
11.1 percentage of eyes
Interval 1.2 to 36.8
|
9.1 percentage of eyes
Interval 1.0 to 31.0
|
0.0 percentage of eyes
Interval 0.0 to 17.5
|
|
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 2: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
10.0 percentage of eyes
Interval 1.0 to 33.7
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
|
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 3: Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
18.2 percentage of eyes
Interval 4.9 to 41.5
|
33.3 percentage of eyes
Interval 15.4 to 55.9
|
|
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 3: Non-Study Eye
|
—
|
—
|
—
|
0.0 percentage of eyes
Interval 0.0 to 25.0
|
18.2 percentage of eyes
Interval 4.9 to 41.5
|
0.0 percentage of eyes
Interval 0.0 to 17.5
|
|
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 9: Study Eye
|
—
|
—
|
—
|
22.2 percentage of eyes
Interval 6.1 to 49.0
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
|
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for BCVA
Month 9: Non-Study Eye
|
—
|
—
|
—
|
22.2 percentage of eyes
Interval 6.1 to 49.0
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
SECONDARY outcome
Timeframe: Months 1, 3, 6, 9, and 12Population: ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a ≥5 letters loss from baseline for LLVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=18 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
Month 1: Study Eye
|
—
|
—
|
—
|
33.3 percentage of eyes
Interval 12.9 to 59.9
|
18.2 percentage of eyes
Interval 4.9 to 41.5
|
41.7 percentage of eyes
Interval 21.9 to 63.8
|
|
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
Month 1: Non-Study Eye
|
—
|
—
|
—
|
33.3 percentage of eyes
Interval 12.9 to 59.9
|
36.4 percentage of eyes
Interval 16.9 to 59.9
|
0.0 percentage of eyes
Interval 0.0 to 17.5
|
|
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
Month 3: Study Eye
|
—
|
—
|
—
|
12.5 percentage of eyes
Interval 1.3 to 40.6
|
18.2 percentage of eyes
Interval 4.9 to 41.5
|
41.7 percentage of eyes
Interval 21.9 to 63.8
|
|
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
Month 3: Non-Study Eye
|
—
|
—
|
—
|
37.5 percentage of eyes
Interval 14.7 to 65.5
|
9.1 percentage of eyes
Interval 1.0 to 31.0
|
0.0 percentage of eyes
Interval 0.0 to 17.5
|
|
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
Month 6: Study Eye
|
—
|
—
|
—
|
22.2 percentage of eyes
Interval 6.1 to 49.0
|
20.0 percentage of eyes
Interval 5.5 to 45.0
|
30.0 percentage of eyes
Interval 11.6 to 55.2
|
|
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
Month 9: Study Eye
|
—
|
—
|
—
|
33.3 percentage of eyes
Interval 12.9 to 59.9
|
22.2 percentage of eyes
Interval 6.1 to 49.0
|
33.3 percentage of eyes
Interval 12.9 to 59.9
|
|
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
Month 9: Non-Study Eye
|
—
|
—
|
—
|
55.6 percentage of eyes
Interval 30.1 to 79.0
|
33.3 percentage of eyes
Interval 12.9 to 59.9
|
0.0 percentage of eyes
Interval 0.0 to 22.6
|
|
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
Month 12: Study Eye
|
—
|
—
|
—
|
55.6 percentage of eyes
Interval 30.1 to 79.0
|
30.0 percentage of eyes
Interval 11.6 to 55.2
|
40.0 percentage of eyes
Interval 18.8 to 64.6
|
|
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
Month 12: Non-Study Eye
|
—
|
—
|
—
|
44.4 percentage of eyes
Interval 21.0 to 69.9
|
40.0 percentage of eyes
Interval 18.8 to 64.6
|
30.0 percentage of eyes
Interval 11.6 to 55.2
|
|
Part 2: Percentage of Eyes With a ≥5 Letters Loss From Baseline for LLVA
Month 6: Non-Study Eye
|
—
|
—
|
—
|
33.3 percentage of eyes
Interval 12.9 to 59.9
|
50.0 percentage of eyes
Interval 26.7 to 73.3
|
0.0 percentage of eyes
Interval 0.0 to 20.6
|
SECONDARY outcome
Timeframe: Months 1, 2, 3, 6, 9, and 12Population: ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
BCVA was assessed for both eyes using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a change from baseline of ≥ -5 letters for BCVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=18 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for BCVA
Month 1: Study Eye
|
—
|
—
|
—
|
88.9 percentage of eyes
Interval 63.2 to 98.8
|
90.0 percentage of eyes
Interval 66.3 to 99.0
|
70.0 percentage of eyes
Interval 44.8 to 88.4
|
|
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for BCVA
Month 2: Non-Study Eye
|
—
|
—
|
—
|
100.0 percentage of eyes
Interval 77.4 to 100.0
|
90.0 percentage of eyes
Interval 66.3 to 99.0
|
100.0 percentage of eyes
Interval 79.4 to 100.0
|
|
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for BCVA
Month 6: Study Eye
|
—
|
—
|
—
|
100.0 percentage of eyes
Interval 77.4 to 100.0
|
88.9 percentage of eyes
Interval 63.2 to 98.8
|
75.0 percentage of eyes
Interval 46.2 to 93.1
|
|
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for BCVA
Month 9: Study Eye
|
—
|
—
|
—
|
100.0 percentage of eyes
Interval 77.4 to 100.0
|
75.0 percentage of eyes
Interval 46.2 to 93.1
|
100.0 percentage of eyes
Interval 72.0 to 100.0
|
|
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for BCVA
Month 1: Non-Study Eye
|
—
|
—
|
—
|
88.9 percentage of eyes
Interval 63.2 to 98.8
|
90.0 percentage of eyes
Interval 66.3 to 99.0
|
100.0 percentage of eyes
Interval 79.4 to 100.0
|
|
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for BCVA
Month 2: Study Eye
|
—
|
—
|
—
|
100.0 percentage of eyes
Interval 77.4 to 100.0
|
80.0 percentage of eyes
Interval 55.0 to 94.5
|
60.0 percentage of eyes
Interval 35.4 to 81.2
|
|
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for BCVA
Month 3: Study Eye
|
—
|
—
|
—
|
100.0 percentage of eyes
Interval 75.0 to 100.0
|
80.0 percentage of eyes
Interval 55.0 to 94.5
|
70.0 percentage of eyes
Interval 44.8 to 88.4
|
|
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for BCVA
Month 3: Non-Study Eye
|
—
|
—
|
—
|
100.0 percentage of eyes
Interval 75.0 to 100.0
|
90.0 percentage of eyes
Interval 66.3 to 99.0
|
100.0 percentage of eyes
Interval 79.4 to 100.0
|
|
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for BCVA
Month 6: Non-Study Eye
|
—
|
—
|
—
|
77.8 percentage of eyes
Interval 51.0 to 93.9
|
100.0 percentage of eyes
Interval 77.4 to 100.0
|
87.5 percentage of eyes
Interval 59.4 to 98.7
|
|
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for BCVA
Month 9: Non-Study Eye
|
—
|
—
|
—
|
77.8 percentage of eyes
Interval 51.0 to 93.9
|
100.0 percentage of eyes
Interval 75.0 to 100.0
|
100.0 percentage of eyes
Interval 72.0 to 100.0
|
|
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for BCVA
Month 12: Study Eye
|
—
|
—
|
—
|
88.9 percentage of eyes
Interval 63.2 to 98.8
|
77.8 percentage of eyes
Interval 51.0 to 93.9
|
87.5 percentage of eyes
Interval 59.4 to 98.7
|
|
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for BCVA
Month 12: Non-Study Eye
|
—
|
—
|
—
|
66.7 percentage of eyes
Interval 40.1 to 87.1
|
88.9 percentage of eyes
Interval 63.2 to 98.8
|
100.0 percentage of eyes
Interval 72.0 to 100.0
|
SECONDARY outcome
Timeframe: Months 1, 3, 6, 9, and 12Population: ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the participant read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If \<20 letters were read at 4 meters, testing at 1 meter was performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of eyes with a change from baseline of ≥ -5 letters for LLVA were reported for study and non-study eyes.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=18 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for LLVA
Month 1: Study Eye
|
—
|
—
|
—
|
66.7 percentage of eyes
Interval 40.1 to 87.1
|
80.0 percentage of eyes
Interval 55.0 to 94.5
|
70.0 percentage of eyes
Interval 44.8 to 88.4
|
|
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for LLVA
Month 1: Non-Study Eye
|
—
|
—
|
—
|
66.7 percentage of eyes
Interval 40.1 to 87.1
|
60.0 percentage of eyes
Interval 35.4 to 81.2
|
100.0 percentage of eyes
Interval 79.4 to 100.0
|
|
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for LLVA
Month 6: Study Eye
|
—
|
—
|
—
|
77.8 percentage of eyes
Interval 51.0 to 93.9
|
77.8 percentage of eyes
Interval 51.0 to 93.9
|
75.0 percentage of eyes
Interval 46.2 to 93.1
|
|
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for LLVA
Month 6: Non-Study Eye
|
—
|
—
|
—
|
66.7 percentage of eyes
Interval 40.1 to 87.1
|
44.4 percentage of eyes
Interval 21.0 to 69.9
|
100.0 percentage of eyes
Interval 75.0 to 100.0
|
|
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for LLVA
Month 9: Study Eye
|
—
|
—
|
—
|
66.7 percentage of eyes
Interval 40.1 to 87.1
|
75.0 percentage of eyes
Interval 46.2 to 93.1
|
71.4 percentage of eyes
Interval 40.4 to 92.1
|
|
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for LLVA
Month 9: Non-Study Eye
|
—
|
—
|
—
|
44.4 percentage of eyes
Interval 21.0 to 69.9
|
62.5 percentage of eyes
Interval 34.5 to 85.3
|
100.0 percentage of eyes
Interval 72.0 to 100.0
|
|
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for LLVA
Month 12: Study Eye
|
—
|
—
|
—
|
44.4 percentage of eyes
Interval 21.0 to 69.9
|
66.7 percentage of eyes
Interval 40.1 to 87.1
|
75.0 percentage of eyes
Interval 46.2 to 93.1
|
|
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for LLVA
Month 12: Non-Study Eye
|
—
|
—
|
—
|
55.6 percentage of eyes
Interval 30.1 to 79.0
|
55.6 percentage of eyes
Interval 30.1 to 79.0
|
62.5 percentage of eyes
Interval 34.5 to 85.3
|
|
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for LLVA
Month 3: Study Eye
|
—
|
—
|
—
|
87.5 percentage of eyes
Interval 59.4 to 98.7
|
80.0 percentage of eyes
Interval 55.0 to 94.5
|
60.0 percentage of eyes
Interval 35.4 to 81.2
|
|
Part 2: Percentage of Eyes With Change From Baseline >-5 Letters for LLVA
Month 3: Non-Study Eye
|
—
|
—
|
—
|
62.5 percentage of eyes
Interval 34.5 to 85.3
|
100.0 percentage of eyes
Interval 79.4 to 100.0
|
100.0 percentage of eyes
Interval 79.4 to 100.0
|
SECONDARY outcome
Timeframe: Baseline, Months 3, 6, and 12Population: ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Visual field testing was performed to assess the volume of 30-degree hill vision, reported as dBs. RF=number of false positive responses + number of false negative responses/number of false positive presentations + number of false negative presentations\*100. If there are 0 responses, then RF value=0. RFpositive=number of false positive responses/number of false positive presentations\*100. If RF≤ 20% measurement is considered reliable. If 20% \< RF ≤ 25% and RFpositive ≤ 10% measurement is also considered reliable. Otherwise if 20% \< RF ≤ 25% and RFpositive \> 10%, or RF \> 25%, measurement is not reliable. Only reliable measurements were included for analysis of this outcome measure. Here negative values indicate decline in the volume of 30-degree hill vision.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=16 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 2: Change From Baseline in Volume of 30-Degree Hill of Vision Assessed by Octopus 900
Change From Baseline at Month 3: Study Eye
|
—
|
—
|
—
|
0.80 dBs
Standard Deviation 1.236
|
0.63 dBs
Standard Deviation 1.162
|
-0.01 dBs
Standard Deviation 5.288
|
|
Part 2: Change From Baseline in Volume of 30-Degree Hill of Vision Assessed by Octopus 900
Change From Baseline at Month 6: Non-Study Eye
|
—
|
—
|
—
|
0.20 dBs
Standard Deviation 0.516
|
0.30 dBs
Standard Deviation 0.665
|
0.19 dBs
Standard Deviation 0.576
|
|
Part 2: Change From Baseline in Volume of 30-Degree Hill of Vision Assessed by Octopus 900
Change From Baseline at Month 12: Study Eye
|
—
|
—
|
—
|
-0.36 dBs
Standard Deviation 0.615
|
0.26 dBs
Standard Deviation 1.164
|
-1.91 dBs
Standard Deviation 1.498
|
|
Part 2: Change From Baseline in Volume of 30-Degree Hill of Vision Assessed by Octopus 900
Change From Baseline at Month 12: Non-Study Eye
|
—
|
—
|
—
|
0.29 dBs
Standard Deviation 0.487
|
-0.10 dBs
Standard Deviation 0.781
|
-0.56 dBs
Standard Deviation 0.337
|
|
Part 2: Change From Baseline in Volume of 30-Degree Hill of Vision Assessed by Octopus 900
Baseline: Study Eye
|
—
|
—
|
—
|
3.61 dBs
Standard Deviation 3.436
|
3.58 dBs
Standard Deviation 2.549
|
5.70 dBs
Standard Deviation 3.161
|
|
Part 2: Change From Baseline in Volume of 30-Degree Hill of Vision Assessed by Octopus 900
Baseline: Non-Study Eye
|
—
|
—
|
—
|
3.05 dBs
Standard Deviation 3.223
|
3.71 dBs
Standard Deviation 2.668
|
6.23 dBs
Standard Deviation 2.956
|
|
Part 2: Change From Baseline in Volume of 30-Degree Hill of Vision Assessed by Octopus 900
Change From Baseline at Month 3: Non-Study Eye
|
—
|
—
|
—
|
0.52 dBs
Standard Deviation 1.315
|
0.45 dBs
Standard Deviation 0.759
|
-0.02 dBs
Standard Deviation 1.110
|
|
Part 2: Change From Baseline in Volume of 30-Degree Hill of Vision Assessed by Octopus 900
Change From Baseline at Month 6: Study Eye
|
—
|
—
|
—
|
0.13 dBs
Standard Deviation 0.499
|
0.57 dBs
Standard Deviation 1.354
|
-1.22 dBs
Standard Deviation 1.566
|
SECONDARY outcome
Timeframe: Baseline, Months 3, 6, and 12Population: ITT analysis set included all participants that were randomized under the 3-arm randomization schedules. 'Overall number of participants analyzed' signifies the number of participants with data available for analysis of outcome measure. 'Number analyzed' signifies the number of participants with data available for analysis at specified timepoint.
Visual field testing was performed to assess the volume of full field of hill vision, reported as dBs. RF=number of false positive responses + number of false negative responses/number of false positive presentations + number of false negative presentations\*100. If there are 0 responses, then RF value=0. RFpositive=number of false positive responses/number of false positive presentations\*100. If RF≤ 20% measurement is considered reliable. If 20% \< RF ≤ 25% and RFpositive ≤ 10% measurement is also considered reliable. Otherwise if 20% \< RF ≤ 25% and RFpositive \> 10%, or RF \> 25%, measurement is not reliable. Only reliable measurements were included for analysis of this outcome measure. Here negative values indicate decline in volume of full field hill vision.
Outcome measures
| Measure |
Part 1: BIIB112 Dose 4
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 1
n=16 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=20 eyes
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|
|
Part 2: Change From Baseline in Volume of Full Field Hill of Vision Assessed by Octopus 900
Change From Baseline at Month 3: Study Eye
|
—
|
—
|
—
|
1.84 dBs
Standard Deviation 3.168
|
1.26 dBs
Standard Deviation 3.327
|
-0.10 dBs
Standard Deviation 4.059
|
|
Part 2: Change From Baseline in Volume of Full Field Hill of Vision Assessed by Octopus 900
Baseline: Study Eye
|
—
|
—
|
—
|
7.26 dBs
Standard Deviation 8.624
|
17.51 dBs
Standard Deviation 17.302
|
19.48 dBs
Standard Deviation 16.248
|
|
Part 2: Change From Baseline in Volume of Full Field Hill of Vision Assessed by Octopus 900
Baseline: Non-Study Eye
|
—
|
—
|
—
|
7.05 dBs
Standard Deviation 8.821
|
16.33 dBs
Standard Deviation 16.803
|
21.08 dBs
Standard Deviation 17.560
|
|
Part 2: Change From Baseline in Volume of Full Field Hill of Vision Assessed by Octopus 900
Change From Baseline at Month 3: Non-Study Eye
|
—
|
—
|
—
|
1.36 dBs
Standard Deviation 2.460
|
2.01 dBs
Standard Deviation 2.832
|
0.55 dBs
Standard Deviation 3.097
|
|
Part 2: Change From Baseline in Volume of Full Field Hill of Vision Assessed by Octopus 900
Change From Baseline at Month 6: Study Eye
|
—
|
—
|
—
|
-0.35 dBs
Standard Deviation 1.461
|
0.98 dBs
Standard Deviation 2.197
|
1.52 dBs
Standard Deviation 3.897
|
|
Part 2: Change From Baseline in Volume of Full Field Hill of Vision Assessed by Octopus 900
Change From Baseline at Month 6: Non-Study Eye
|
—
|
—
|
—
|
0.46 dBs
Standard Deviation 1.124
|
0.99 dBs
Standard Deviation 2.324
|
1.38 dBs
Standard Deviation 2.526
|
|
Part 2: Change From Baseline in Volume of Full Field Hill of Vision Assessed by Octopus 900
Change From Baseline at Month 12: Study Eye
|
—
|
—
|
—
|
-1.18 dBs
Standard Deviation 1.302
|
0.81 dBs
Standard Deviation 3.709
|
-0.95 dBs
Standard Deviation 3.992
|
|
Part 2: Change From Baseline in Volume of Full Field Hill of Vision Assessed by Octopus 900
Change From Baseline at Month 12: Non-Study Eye
|
—
|
—
|
—
|
0.66 dBs
Standard Deviation 1.193
|
0.28 dBs
Standard Deviation 2.736
|
-0.91 dBs
Standard Deviation 2.001
|
Adverse Events
Part 1: BIIB112 Dose 1
Part 1: BIIB112 Dose 2
Part 1: BIIB112 Dose 3
Part 1: BIIB112 Dose 4
Part 1: BIIB112 Dose 5
Part 1: BIIB112 Dose 6
Part 2: Untreated Group
Part 2: BIIB112 Low Dose
Part 2: BIIB112 High Dose
Serious adverse events
| Measure |
Part 1: BIIB112 Dose 1
n=3 participants at risk
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=3 participants at risk
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=3 participants at risk
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 4
n=3 participants at risk
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=3 participants at risk
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=3 participants at risk
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 2: Untreated Group
n=9 participants at risk
Participants received no intervention to allow for a controlled comparison.
|
Part 2: BIIB112 Low Dose
n=11 participants at risk
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 2: BIIB112 High Dose
n=12 participants at risk
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|---|---|---|
|
Immune system disorders
Anaphylactic reaction
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Noninfective retinitis
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Retinal detachment
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Subretinal fluid
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
25.0%
3/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Visual acuity reduced
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
16.7%
2/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Visual impairment
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Gastrointestinal disorders
Food poisoning
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Infections and infestations
Appendicitis
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
11.1%
1/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
Other adverse events
| Measure |
Part 1: BIIB112 Dose 1
n=3 participants at risk
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 1 (5 × 10\^9 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 2
n=3 participants at risk
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 2 (1 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 3
n=3 participants at risk
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 3 (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 4
n=3 participants at risk
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 4 (1 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 5
n=3 participants at risk
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 5 (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 1: BIIB112 Dose 6
n=3 participants at risk
Followed by vitrectomy and retinal detachment in the study eye, participants received a single dose 6 (5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 2: Untreated Group
n=9 participants at risk
Participants received no intervention to allow for a controlled comparison.
|
Part 2: BIIB112 Low Dose
n=11 participants at risk
Followed by vitrectomy and retinal detachment in study eye, participants received a single low dose (5 × 10\^10 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
Part 2: BIIB112 High Dose
n=12 participants at risk
Followed by vitrectomy and retinal detachment in study eye, participants received a single high dose (2.5 × 10\^11 vg) of BIIB112 by sub-retinal injection on Day 0 (surgery day).
|
|---|---|---|---|---|---|---|---|---|---|
|
Eye disorders
Iritis
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
18.2%
2/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
16.7%
2/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Lacrimation increased
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
16.7%
2/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Lenticular pigmentation
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Macular fibrosis
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Maculopathy
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Metamorphopsia
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
4/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Noninfective retinitis
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
100.0%
3/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
25.0%
3/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Ocular discomfort
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
18.2%
2/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
16.7%
2/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Ocular hypertension
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Photophobia
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
16.7%
2/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Posterior capsule opacification
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
11.1%
1/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Retinal artery embolism
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Retinal cyst
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Retinal degeneration
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Retinal deposits
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
16.7%
2/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Retinal fovea disorder
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Retinal haemorrhage
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
16.7%
2/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Retinal infiltrates
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Retinal oedema
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Retinal tear
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
16.7%
2/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Retinal thickening
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Retinoschisis
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Scleritis
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Subretinal fluid
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
18.2%
2/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
25.0%
3/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Vision blurred
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
11.1%
1/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
4/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Visual acuity reduced
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
25.0%
3/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Visual impairment
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
25.0%
3/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Vitreal cells
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
4/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Vitreous detachment
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Vitritis
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
41.7%
5/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
16.7%
2/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Gastrointestinal disorders
Stomatitis
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Skin and subcutaneous tissue disorders
Acne
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
25.0%
3/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Skin and subcutaneous tissue disorders
Night sweats
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Musculoskeletal and connective tissue disorders
Chondrocalcinosis pyrophosphate
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Infections and infestations
Bursitis infective
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
11.1%
1/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Infections and infestations
Conjunctivitis
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Infections and infestations
Ear infection
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Infections and infestations
Gastroenteritis
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Infections and infestations
Hypopyon
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Infections and infestations
Infected dermal cyst
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Infections and infestations
Influenza
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Infections and infestations
Lower respiratory tract infection
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
18.2%
2/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
18.2%
2/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
11.1%
1/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
11.1%
1/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Ear and labyrinth disorders
Eustachian tube dysfunction
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Aniseikonia
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Anterior chamber cell
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
45.5%
5/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
50.0%
6/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Anterior chamber flare
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
25.0%
3/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Nervous system disorders
Visual field defect
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Injury, poisoning and procedural complications
Dysphotopsia
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Vascular disorders
Hot flush
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Vascular disorders
Hypertension
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Surgical and medical procedures
Tooth extraction
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Immune system disorders
Multiple allergies
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Immune system disorders
Seasonal allergy
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Respiratory, thoracic and mediastinal disorders
Bronchiectasis
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
22.2%
2/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Psychiatric disorders
Depression
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Investigations
Blood creatinine increased
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Investigations
Blood glucose increased
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Investigations
Blood triglycerides increased
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Investigations
Intraocular pressure decreased
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Investigations
Intraocular pressure increased
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
66.7%
2/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
11.1%
1/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
54.5%
6/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
41.7%
5/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Investigations
Lymphocyte count decreased
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Investigations
Neutrophil count increased
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
18.2%
2/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
4/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Investigations
Visual field tests abnormal
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Investigations
Vitamin d decreased
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Investigations
White blood cell count increased
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
16.7%
2/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Injury, poisoning and procedural complications
Corneal abrasion
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Injury, poisoning and procedural complications
Eye contusion
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Injury, poisoning and procedural complications
Muscle rupture
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Injury, poisoning and procedural complications
Ocular procedural complication
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
16.7%
2/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Injury, poisoning and procedural complications
Post procedural discomfort
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Injury, poisoning and procedural complications
Post procedural inflammation
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Injury, poisoning and procedural complications
Post-traumatic neck syndrome
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Injury, poisoning and procedural complications
Post-traumatic pain
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Injury, poisoning and procedural complications
Procedural pain
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
16.7%
2/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Injury, poisoning and procedural complications
Skin laceration
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
11.1%
1/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Injury, poisoning and procedural complications
Suture related complication
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
41.7%
5/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
11.1%
1/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Cardiac disorders
Palpitations
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
11.1%
1/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Nervous system disorders
Dizziness
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Nervous system disorders
Headache
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
18.2%
2/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Nervous system disorders
Tunnel vision
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Anterior chamber inflammation
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
66.7%
2/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
18.2%
2/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Asthenopia
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Blepharitis
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Blindness transient
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Cataract
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
11.1%
1/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
27.3%
3/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
25.0%
3/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Cataract subcapsular
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Choroidal detachment
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Chromatopsia
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Conjunctival haemorrhage
|
100.0%
3/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
54.5%
6/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
75.0%
9/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Conjunctival hyperaemia
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Conjunctival irritation
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Conjunctival oedema
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Corneal deposits
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Cystoid macular oedema
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
18.2%
2/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
4/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Delayed light adaptation
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Detachment of macular retinal pigment epithelium
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Diplopia
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Dry eye
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Dyschromatopsia
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Eye inflammation
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
66.7%
2/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
16.7%
2/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Eye pain
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
18.2%
2/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
16.7%
2/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Eye pruritus
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Eyelid oedema
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Eyelid ptosis
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
8.3%
1/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Foreign body sensation in eyes
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
9.1%
1/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
16.7%
2/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Hypotony of eye
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
|
Eye disorders
Iridocyclitis
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
33.3%
1/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/3 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/9 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/11 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
0.00%
0/12 • Day 0 (surgery) in Part 1 of the study up to last follow up visit in Part 2 of the study (approximately 36 months)
Safety analysis set consists of all participants who received study treatment (vitrectomy/BIIB112).
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee Our agreement is subject to confidentiality but generally, the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor's Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of the Sponsor's intellectual property contained in the proposed publication.
- Publication restrictions are in place
Restriction type: OTHER